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Abstract
Epilepsy is a common disease world-wide whose suggested treatment vary from
surgical to non-surgical. Although surgical treatments may be commonly recom-
mended and successful in pharmacoresistant epilepsy for patients with refractory
epilepsy, there are some patients who experience a seizure relapse. It is of interest to
medical practitioners to determine how long patients survive epilepsy after a suc-
cessful surgery. Survival analysis methods have been used to model time-to-event
data. Hence we attempt to determine the time to a seizure relapse in epilepsy pa-
tients after a surgery. However, single study have some limitations, such as lack of
accommodation of spatial factors, different research approaches to mention a few.
Most of the time, single studies are under-powered to detect the factors of covari-
ates. Meta-analysis methods have been developed to overcome this problem, where
a number of studies are amalgamated and a common conclusion is drawn. This the-
sis aims is to determine the long-term seizure outcome after an epilepsy surgery of
refractory epilepsy without focusing on the types of refractory but rather in resective
surgery. In the current study a systematic review was done using Google Scholar,
Medline, and PubMed. The event of interest is seizure relapse and our interest is to
pool the time to first seizure relapse after surgical treatment. To measure the seizure
freedom the clinical method call Engel class I was used. The univariate and meta-
survival of fixed and random effect model were used to measure the proportion of
seizure freedom. Our focus was only in single arm treatment (surgical treatment) .
There were a total of 18 studies that satisfy the inclusion criteria with observations
at 6 time points measured in months after post-operative (6, 12, 24, 36, 60 and 120
months). In the univariate analysis, the probabilities of seizure freedom of the fixed
effects models were systematically larger than the random effect results. There was
evidence of significance of heterogeneity between studies, and the true variation
between studies test was large. The result that we got in univariate random effect
model were for time-points 6, 12, 24, 36, 60 and 120 months were 0.74 95% confidence
interval (CI)(0.66- 0.82), 0.69 95% CI (0.61- 0.77), 0.64 95% CI (0.56- 0.71), 0.60 95% CI
(0.52- 0.68), 0.56 95% CI (0.48- 0.63) and 0.47 95% CI (0.38- 0.56) respectively. The
meta-survival analysis also systematically showed that, the seizure free probability
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were larger in a fixed effects model than in a random effects model. The summary
survival estimates of the random effect model that were pooled in the following time
points 6, 12, 24, 36, 60 and 120 were 0.7655 95% CI (0.6808- 0.8613), 0.7140 95% CI
(0.6246- 0.8163), 0.6462 95% (0.5614, 0.7438), 0.6105 95% (0.5225, 0.7133), 0.5700 95%
(0.4892, 0.6641) and 0.4755 (0.4078, 0.5545) respectively. The median time to relapse
was found using the meta-survival analysis in random effects model to be 104.46
months (8.87 years). We can conclude that the meta-survival analysis may be the
method to pool the time-to-event data in one-arm treatment..
Keywords: Refractory epilepsy, long-term seizure, meta-analysis, univariate, meta-
survival analysis
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Chapter 1
Introduction
1.1 Chapter overview
This chapter overviews and presents literature on epilepsy and how it threatens the
quality of life in individuals and in the world at large, especially in developing coun-
tries. It also reviews drug resistant epilepsy (DRE) as well as the treatments that are
available. Furthermore, it outlines the motivation of the thesis; research question;
justification of the study; and the aims and objectives of the study.
1.2 Background information of epilepsy
1.2.1 Introduction to epilepsy
Epilepsy is the most common and dilapidating neurological disorder (Hirtz et al.,
2007) that affected approximately 22 million people by 2013 world-wide (Vos et al.,
2016). It affects 1% of people in their 20s and 3% of those in their 75s (Browne &
Holmes, 2008). It is more common in males than in females, although there are
few data from developing countries (Newton & Garcia, 2012; Neligan et al., 2012).
Epilepsy patients are at an increasing death risk-between 1.6 and 4.1 ( which is ex-
pressed as a standardized mortality ratio) which is larger than the general popula-
tion (Hitiris et al., 2007; Shorvon et al., 2015a). Those cases of death can be caused
by the underlying causes of seizure, status epilepticus, suicide, trauma or sudden
unexpected death (Hitiris et al., 2007). The risk of suicide is also reported as being
much higher for those with epilepsy (Bagary, 2011; Mula & Sander, 2013)) compared
to non-epilepsy individuals.
A seizure may be a transient incidence of signs and/or symptoms because of ab-
normal excessive or synchronous neuronic activity within the brain (Fisher et al.,
1
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2014). The term transient is used as demarcated in time, with a clear beginning and
completion (Trinka et al., 2015). Epilepsy is, therefore, a group of neurological dis-
eases characterized by epileptic seizures (Fisher et al., 2014; Chang & Lowenstein,
2003; WHO, 2016) that may vary briefly, and nearly undetectable, to prolonged pe-
riods of vigorous shaking (WHO, 2016). In several cases, the explanation for brain
disease is unknown however are often genetically or acquired, with the interaction
of things like traumatic brain injury, stroke, head tumors, single genetic disease (1-
2%) or brain disorders (Berkovic et al., 2006; Pandolfo, 2011; Aminoff et al., 2012).
Fisher et al. (2014) as a neurological disorder which will be attributed a minimum
of one in every of these conditions: a minimum of 2 unwanted seizures occur within
the course of a day; one unprovoked sseizure and a likelihood of any seizures just
like general repeat risk a minimum of 60% after two unprovoked seizures, occurring
over the next ten years. This can be used for the diagnosis of epilepsy.
Epilepsy is not preventable (Zaidi et al., 2000) but to know the definition, classifi-
cation, syndrome, and test, can be helpful with the diagnosing (managing) epilepsy
(Zaidi et al., 2000; Akhtar, 2002; Engel et al., 2013; Wilden & Cohen-Gadol, 2012;
WHO, 2016). In many cases, the treatment to be given to the patient is determined
based on these characteristics. Although medication can control the successful man-
agement of 70% cases (Eadie, 2012), treatment in the developing world is still low.
Approximately 75% of epilepsy patients are either untreated or not appropriately
treated (WHO, 2016). Approximately 90% of epilepsy patients do not receive med-
ication either due to unavailability of treatments or it is too expensive for the gov-
ernment to make it available for free to the public (WHO, 2016). There are also
epilepsies that are not easy to diagnose.
1.2.2 Epilepsy in the developing world
In a study done by Seneneyake & Román (1993) for developing countries, it had
been found that epilepsy was high in Latin America, Liberia, Nigeria and the United
Republic of Tanzania. Most significantly, the etiology issue was parasitic infection
common in tropical countries and a few elements of Africa; and infection of bacteria,
viral origin, perinatal brain damage, head injury, toxic agent and heredity factors
were important in explaining the high prevalence of epilepsy.
Newton & Garcia (2012) and Birbeck et al. (2002) noted that there’s a treatment
gap within the health care of every and each country within the developing world,
principally for those between urban dwellings and rural areas. This could be as a
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result of, in urban areas, there’s easier access to health facilities than outside urban
areas. The shortage of brain disease medical specialty facilities in several develop-
ing countries and few neurologists to assess those with brain disease and restricted
electroencephalography (EEG) testing, X-ray X-raying (CT) scans, and Magnetic res-
onance imaging (MRI) to verify diagnoses of brain disease(Birbeck et al., 2002) also
contribute to the poor diagnosis of epilepsy.
1.2.3 Impact of epilepsy in quality of life
The quality of life (QOL) is largely the health of people and communities (Barcac-
cia, 2013). This may be outlined by characteristics that ar noticeable in fulfillment of
life (where these options ar taken as important) for instance, physical health, fam-
ily, education, employment, wealth, spiritual beliefs and therefore the atmosphere
(Barcaccia, 2013).
Epilepsy is attended with profound physical, psychological and social consequences
and also the impact of uncontrolled brain disorder on a personality’s quality of life
is bigger than that of another chronic conditions, like diabetes, cancer or cardiovas-
cular disease to mention the few (Reynolds, 2001). Many studies have found that the
upper the seizure severity the lower the standard of life, particularly in social living
(Harden et al., 2007; Téllez-Zenteno et al., 2005; Wieser & Hane, 2003; Gholami et al.,
2016; Seneneyake & Román, 1993).
Gholami et al. (2016) argue that with correct epilepsy management, more than
three-quarters of individual with epilepsy can get regular health and even get seizure
freedom. Features that are essential when explaining the impact of epilepsy on qual-
ity of life are: education (especially for individuals who previously received inade-
quate schooling); employment (unemployment in people living with epilepsy is 2 to
3 times higher than people living with other disabilities) and independence (people
with epilepsy may have experienced some physical disability which may limit their
independence) (Gholami et al., 2016).
1.2.4 Drug resistant epilepsy
Although epilepsy can be treated using drugs, such as anti-epileptic drug (AED), this
is also a fact that there are other drug resistant epilepsy (DRE). This is also known
as refractory epilepsy or pharmacoresistant epilepsy, which is defined as the failure
of adequate trials of two dosages controlled and appropriately chosen anti-epileptic
drug (AED) to support seizure freedom (Kwan et al., 2010). The important reason
for using treatment to control seizure is to achieve seizure freedom which is better
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for maintaining the quality of life and cognitive function (Elger & Schmidt, 2008). It
can be estimated that one third of patients with epilepsy are drug-resistant (Brodie,
2013). To maintain the quality of life in the patient with epilepsy it is recommended
that any treatment to control seizures or achieve seizure freedom should be used.
The most suggested treatment to treat drug resistant epilepsy is epilepsy surgery
which can be either a resective or disconnective procedure (Clinic, 2018). According
to (Bromfield et al., 2006; Clinic, 2018; Engel et al., 2013) the resective procedure, is
the removal of the part of the brain that causes the seizure is performed, while in the
disconnective procedure, the neural connections in the brain that allows the seizure
to spread are disconnected. Any patients can be referred by their physician to any
epilepsy center for pre-surgery evaluation. The magnetic resonance tomography is
used as the imaging technique, and to pinpoint the focus of epileptic seizure the
electrocorticography is used.
Even though the surgical treatment seems successful in refractory epilepsy pa-
tients, it is not 100 % effective in achieving seizure freedom (Engel, 2013, 1993). In
recent studies, it was found that seizure freedom varies with types of surgery. Sirven
(2013) mentioned that 30 - 50 % of patients achieved seizure freedom while in 20 -
40 % who had epilepsy recurrence post-operative patients, the seizure is reduced at
least by 90 % and at least 70 % of patients achieved seizure diagnosed with AED. In
temporal lobectomy about 60 - 70 % achieved seizure freedom, and in 20 - 25% of
those with epilepsy recurrence, the seizure will be reduced by 85 % (Téllez-Zenteno
et al., 2005). As such, this study is more focused on investigating the seizure freedom
over time after surgery where the event of interest is the first recurrence of seizure
post-operative.
Tetto et al. (2002) mention that in Italy they found that the annual cost for seizure
treatment is 412 Euros, 2198 Euros for drug resistant patients and 945 euros for sur-
gical candidates. It is clear that surgical treatment more expensive than that of non-
drug resistant epilepsy, but drug resistant candidate epilepsy costs triple the price of
surgical treated epilepsy (Begley & Beghi, 2002; Tetto et al., 2002). This puts a strain
on the economy, especially on those countries where treatment is provided by the
government.
1.3 Research motivation
Although surgery might be the most recommended treatment, it may have some
unforeseen drawbacks. Relapse is one of the undesired outcomes of a seizure opera-
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tion. Sometimes it is a result of an unsuccessful surgery. Unsuccessful surgery might
be caused by surgery heterogeneity , incorrect localizing or incomplete resection of
the seizure focus or progression of underlying disease.
This study is focused on determining time until relapse of seizure post-operative.
The statistical method that is mostly used to determine time-to- event is survival
analysis. It has an advantage of the ability to handle the censored events. However,
single studies have been proved to have their own disadvantage (Ishak et al., 2007;
Borenstein et al., 2009; Taghavi, 2014; Arends et al., 2008; Rosenthal, 1991). The in-
troduction of meta-analysis methods addresses this problem as such Glass (1976);
Glass et al. (2009); Simpson & Pearson (1904) proposed to integrate studies to inves-
tigate how to increase the chance of controlling epilepsy and educate those affected
and/ or infected by epilepsy to be aware of other treatments of epilepsy. This will
help to inform policy makers in their decision making regarding epilepsy; hence
contribution to the body of knowledge regarding the factors associated with death
by epilepsy and the other available treatment for refractory epilepsy .
1.4 Research questions
Since the surgical treatments are much more costly compared to the non-drug resis-
tant epilepsy we would expect them to be more difficult to access even if possibly
more effective. It is important to find out how effective they are. The following ques-
tions might arise: can government invest in this kind of treatment to achieve a better
quality of life in individuals? Specifically, is there a chance that after a surgical treat-
ment, the patient may relapse? If so, what is the median (survival) time to relapse?
What factors are associated with relapse?
1.5 Study justification
The focus of the study in determining if surgical treatment has a long-term or life-
long effect by combining the studies that investigate the same matter. Meta-analysis
is the statistical method that is introduced to combine different studies to determine
the consistency of these studies (Ishak et al., 2007; Borenstein et al., 2009; Arends,
2006). If there is consistency, the efficiency of surgical epilepsy treatment can be
concluded.
1.6 Aims and objectives
The main objectives of the study are to:
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1) Combine studies that focus on the long-term outcomes that are important after
brain epilepsy surgery.
2) Consider studies that meet the inclusion criteria. That can be analysed using a
meta-analysis approach.
3) Overview of the survival analysis when following up epilepsy patients after surgery
in each of the studies, that is, those studies that use seizure freedom on patients and
determine which statistical effect sizes (like odds ratio, hazard ratio, and so on) were
used to analyse the results.
4) Meta-analysis will be used to determine the pool proportion of survival (seizure
freedom) post-surgery, using the inverse variance weight as well as determinants of
seizure relapse.
5) Test for inter-variation in those included studies.
6) Determine the long-term success of epilepsy surgery.
7) Determine the median time to relapse from epilepsy surgery
1.7 Structure of the study
Chapter one we were reviewing the background of epilepsy, research questions, re-
sarch motivation, research justification and the aims and objectives of the research.
In chapter two reviews the survival analysis for both the classic and its current mod-
ifications. In chapter three the study reviews the meta-analysis statistical method
which is the standard method (fixed and random effects model) that will play a key
role in achieving research goals. Chapter four discusses how a systematic review
was carried out as well as descriptive statistics. Statistical software that will be used
to analyse the data is stated. Chapter five and six gives the result from the analysed
data. Chapter seven gives the conclusion of the study and possible future work.
1.8 Summary
In this chapter, we were reviewing the background of epilepsy (especially, the defi-
nition of epilepsy, epilepsy in the developing world, refractory epilepsy and cost of
epilepsy ). We also discussed the research question, motivation of research, research
justification and the aims and objectives of this thesis. At the end of this chapter, the
structure of this thesis was discussed. Most of this background will play an impor-
tant role when we analyzed and draw the conclusion of this research.
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Chapter 2
Survival analysis in epilepsy
In this chapter, an overview of survival analysis and its importance in epilepsy stud-
ies will be done. Survival analysis can be used to determine how long it takes pa-
tients to have the first seizure after surgery in the context of time-to-event analysis.
2.1 Overview of survival analysis
Survival analysis is a statistical tool that can be used when time-to-event needs to
be modeled with longitudinal data (Collett, 2015; Allison, 2010). It is preferred due
to its ability to handle censored data, time-dependent variables and is suitable for
longitudinal data. Most importantly rather treating the event of interest as a binary
outcome the analysis also takes the time-to-event into account. In the case of cen-
soring, a technique is devised that associates the information in the censored and
non-censored cases in a way that produces a consistent estimates.
Survival analysis uses data in the form of times from a well-distinct time origin
until the occurrence of an event of interest (Clayton, 1978). Such events are generally
referred to as failure or end-point where the time can be measured in days, weeks,
years and so on (Collett, 2015). The Time origin is usually the beginning of the study
before the event of interest occurs. A subject is followed over a specific period of time
until the event of interest occurs, or until the subject is censored, or until the end of
the study. Allison (2010) explains it as a qualitative change that can be positioned in
time where the qualitative change is a transition from one discrete state to another.
In the application of survival analysis, the time of change occurrence (event) must be
known. A transition occurs instantaneously that will make the actual time of onset
unknown. The best observation plan is prospective for survival analysis, where
you begin observing a set of individuals at some well-defined point of time and
you follow them for some substantial period of time, taking the time at which the
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event occurs into consideration (Allison, 2010). In this study we are interested in
time to seizure relapse after an epilepsy surgery. The time to event of interest will
start ticking at day of surgery, and subjects who do not experience a relapse are
considered to be censored.
2.2 Features of survival data
The survival data can be collected over a long period of time (longitudinal data) and
it can be about timing of an event or time to event data (Allison, 2010; Kaplan &
Meier, 1958; Kleinbaum & Klein, 2010). Mostly in biostatistics, the data arises from
cohort studies, clinical trials or intervention studies. The most important elements
in survival analysis are: time of origin, the event of interest and the time between
them (these terms may vary depending on the author but their meaning is the same)
(Clayton et al., 1993; Collett, 2015)). Survival data is non-normal data, which con-
tains time dependent variables, and since it is from the follow-up studies in most
cases it contains censored events.
2.2.1 Non-Normal data
Most cases of survival data arise from observation of individuals from the onset of
risk until the event occurs (Vaupel et al., 1979). The event may occur between the
time of origin and the end of follow-up. At the beginning of the study, the survival
probability is 100% but as some individual experience the event, the probability of
survival continues reducing. This results in positively skewed data, thus violating
the assumption of normality which is required by most standard statistical methods
(Allison, 2010). It is also seems impossible to model survival data using the dichoto-
mous method, since its interest is to model the occurrence of an event only. The best
technique that has been designed to model this kind of data is survival analysis,
which also has the ability to handle time-dependent variables (Kleinbaum & Klein,
2010).
2.2.2 Censoring
The second distinct feature of survival data is censoring. For uncensored outcome it
means the event of interest has occurred for such individuals and their waiting time
for the event of interest is known, while if an individual is censored for the event all
we know is that waiting time exceeds the observed time (Allison, 2010; Vaupel et al.,
1979). Since this is always the case in longitudinal data ( because of drop out, or
the study end before some individuals experience the event), there must be a better
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method of handling censored events. Allison (2010) stated that it is important to
handle censoring events in the analysis, to avoid biased parameter estimates.
There are three types of censoring (Kleinbaum & Klein, 2010) namely:
i) Right censoring is when the event occurs after the observed time. In this case, the
censoring time is less than the actual survival time. It is usually a result of dropout
or study ending before observing the event.
ii) Left censoring is when the event happened before the beginning of the study;
here the actual survival time is less than the observed censoring time.
iii) Interval censoring occurs when the event is known to have happened in an inter-
val of time but the actual survival time is not known.
2.3 Survival analysis common terminology
The two most important terms that are used to explain the time of occurrence of an
event, are survival function and hazard function.
2.3.1 Survival function
The survival time can be defined as the measured length of time from a specific
time origin until the event of interest occurred (Kleinbaum, 1998) (time of epilepsy
surgery can be regarded as time origin). The main concept in survival analysis is to
model the time to event, which we can call survival time (Wienke, 2010). Therefore
the survival function gives the probability that an individuals survives longer than
some specified time (Allison, 2010; Kleinbaum, 1998; Wienke, 2010). For example
the probability of a patients having seizure relapse after a brain surgery being longer
than time t. It is important, before analysing the survival data to know time origin,
time interval of observation and the definition of an event must be clear.
For a group of individuals i = 1, 2, ...., nwith actual survival times t1, t2, ...., tj , ..., tn,
these can be regarded as the observed values of a random variable T , which takes
non-negative values. The survival function, S(t) gives the probability that the ran-
dom variable T exceeds the specified time t (Kleinbaum & Klein, 2010; Cox, 1972).
This is given by:
S(t) = P (T > t) = 1− F (t) (2.1)
where F (t) is the cumulative density function. Since S(t) is the probability of surviv-
ing beyond time t, it should be noted that survival when t = 0, is 1 (that is S(0) = 1)
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and as t → ∞, S(t) → 0. It is a positively skewed function that can be estimated
using the Kaplan-Meier estimation (Wienke, 2010; Kaplan & Meier, 1958).
2.3.2 Hazard function
The hazard function gives the instantaneous failure rate at time t given that the in-
dividual has survived up to time t. It is given by:
λ(t) = lim
∆t→0
1
∆t
P (t ≤ T ≤ t+ ∆t|T ≥ t) (2.2)
The cumulative hazard function can then be given as:
Λ(t) =
∫ t
0
λ(u)du (2.3)
2.3.3 Relationship of Survival and Hazard Function
The hazard and survival functions can be estimated from the observed data (Clayton
et al., 1993; Collett, 2015). The relationship that we are going to discuss is between
S(t), f(t) and λ(t) showing that if one of these functions is given you can be able to
obtain the other functions. When dealing with continuous variables the probability
density function is given by
f(t) = lim
∆t→0
1
∆t
P (t ≤ T ≤ t+ ∆t) = F ′(t) = −S′(t) (2.4)
hence from equation 2.4 it can be shown that hazard rate at time t is given by
−d
dt
[log(S(t))] = −
[
1
S(t)
]
S
′
(t) =
f(t)
S(t)
= λ(t) (2.5)
since we know that:
Λ(t) =
∫ t
0
λ(u)du =
∫ t
0
f(u)
S(u)
du =
∫ t
0
−d
du
[log(S(u))] = − log(S(t))
hence
S(t) = e−Λ(t)
2.4 Estimation methods
The survival and hazard function discussed in section 2.3 above can be estimated in
three ways, namely: non-parametric, semi-parametric and parametric methods.
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2.4.1 Non-parametric estimation
The non-parametric estimation can be used to explore and describe the time to event
data, without putting any constraints on the data with no assumption about any
specific parametric distribution (Allison, 2010; Kleinbaum, 1998).
Kaplan-Meier estimation
In a single sample of survival times, where none of the observation is censored, sur-
vival function can be estimated by the empirical survival function which is defined
as:
Ŝ(t) =
number of individual with(T > t)
total sample size
.
It is assumed to be constant between two adjacent event times and the plot of es-
timated survival function against t is a step function and the function decreases
after each observed survival time. However, when there are censored observa-
tions, we introduce the method that can handle the censoring correctly; which is
a non-parametric method for estimating survival function, proposed by Kaplan &
Meier (1958) also called product limit or Kaplan Meier estimate. This, in fact, is
the non-parametric maximum likelihood that gives rigid a theoretical justification.
The Kaplan-Meier method estimates the survival function when an event occurs
but also fakes account of censoring by adjusting the risk set appropriately (Wienke,
2010). Suppose we have A1, A2, ...Ak different events, the probability of all k events
occurring together, can be written as the product of conditional probabilities.
P (A1∩A2∩...∩Ak) = P (Ak|Ak−1∩Ak−2∩...∩A1)(Ak−1|Ak−2∩Ak−3∩...∩A1)×.....(A2|A1)P (A1)
In the estimate S(t) let us suppose that ak < t ≤ ak+1) then:
S(t) = P (T ≥ ak+1)
= P (T ≥ a1, T ≥ a2, ...., T ≥ ak+1)
= P (T ≥ a1)
k∏
j=1
P (T ≥ aj+1|T ≥ aj)
=
k∏
j=1
[1− P (T = aj |T ≥ aj)]
=
k∏
j=1
[1− λj ]
let dj denote the number of events at time aj , and rj is the number at risk at time aj ,
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then the product limits formula can be given by:
Ŝ(t) ∼=
k∏
j=1
[
1− dj
rj
]
=
k∏
j:aj<t
[
1− dj
rj
]
(2.6)
Even though it is a non-parametric estimate like all likelihood estimates, the variance
must also be estimated. Collett (2015) shows that variance is derived using the delta
method leading to what is known as the Greenwoods formula and is given as:
V̂ arŜ(t) = [Ŝ(t)]2
∑
j:τj<t
dj
(rj − dj)rj
(2.7)
Once the survivor function is estimated one can determine the median survival time
as maximum tm such that Ŝ(tm) ≤ 0.5.
Life tables
The life table estimator of the survival function is used when one is faced with ag-
gregated data instead of individual survival times as for the Kaplan-Meier estima-
tor(Collett, 2015). The product limit formula can be used as we did with the K-M
equation 2.6, but there is a need to specify the number of individuals at risk, ( rj , in
the time interval (tj−1, tj ,)). Denote censoring events at this (tj−1, tj ,) interval as cj ,
then we can assume that half of the individuals were censored at the start of the year
and half at the end. Then number at risk can be modified as:
r′j = rj −
cj
2
(2.8)
and the probability of failure in an interval (tj−1, tj ,) is estimated by :
pj =
dj
r′j
(2.9)
The probability of surviving the interval (tj−1, tj ,) is (1 − pj), so the probability of
surviving up to the end of interval (tj−1, tj ,) is:
Ŝ(t) =
k∏
j:aj<t
[
1− dj
r′j
]
(2.10)
Nelson-Aalen estimation of cumulative hazard
The Nelson-Aalen estimator of the cumulative hazard function is given by
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Λ̂(tj) =
∑
j=1
λjδ (2.11)
which is the summation of product of the value of hazard in jth interval and δ is the
width of each intervals. Since the λjδ can be taken as the probability of the event
occurring in the interval, we can further say
Λ̂(tj) =
∑
j=1
dj
rj
(2.12)
Λ̂NA(t) =
∑
j:rj<t
dj
rj
(2.13)
.
2.4.2 Semi-parametric estimation
The semi-parametric model has non-parametric and parametric model components.
An example of the semi-parametric method that is popular is the Proportional Haz-
ard Model (PHM) which was first developed by Cox (1972). It is a multivariate
technique for analyzing the effect of two or more variables on survival. It has com-
monly been used in most analyses to build the determinants of risk of occurrence
of an event. The assumption underlying this model is that there is a hazard at the
duration of the occurrence of an event (Trussell & Bloom, 1983).
The hazard function for individual i is written as :
hi(t) = h0(t) exp(X
T
i β) (2.14)
where h0(t) is the baseline hazard function for an individual whose covariates all
have the values of zero. For individual i, Xi = (xi1, xi2, ...., xip) is the vector of p
covariates and β is the co-efficient associated with each of the p covariates.
Equation 2.14 means that the hazard rate for individual i is the product of two
factors:
i) A baseline hazard function h0(t) that is left unspecified, except that it cannot be
negative.
ii) An exponentiated function of a set of vector of covariate.
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A measure of the effect of a covariate is determined by the hazard ratio (that is
the ratio of two hazard rates). For example, hazard ratio of individuals i and j for a
covariate x, like gender, whose regression co-efficient is common β, is given by
hi(t)
hj(t)
=
h0(t) exp(x
T
i β)
h0(t) exp(xTj β)
= exp(β(xi − xj)) (2.15)
which is clearly a function that is free from t (time) only if x is not time-dependent
variable. The proportional hazards function has a hazard for any individual which
is a fixed proportion of the hazard. Its hazard ratio is not affected by the baseline
hazard. So in the equation 2.15 here the h0(t) cancels out. As a result, the ratio of
the hazard is constant over time because the right hand term in equation 2.15 does
not vary with time. The graph of the log hazards for individuals i and j, should be
strictly parallel. If the hazard ratio is greater than 1 that means the hazard rate of
individual i is great than that of j; if the hazard ratio is less than 1 the vice-versa
is true; and if the hazard ratio is equal to one that means there is no difference in
hazard ratio.
2.4.3 Parametric estimation
As opposed to semi-parametric estimation described in section 2.4.2, where the base-
line hazard was left unspecified in parametric estimation, the baseline hazard is
assumed to follow some distribution. In parametric estimation of baseline hazard
function depends on known statistical distributions that are mainly used in time-to-
event data hence maximum likelihood estimation can be used analytically or itera-
tively. Weibull, Exponential, and Gompertz are some of the well known parametric
models that can be used to model the survival time data (Kleinbaum, 1998; Collett,
2015; Allison, 2010). In this subsection there is an overview of those models.
Exponetial Distribution
The hazard function for the exponential distribution is constant, given by
h0(t) = λ. (2.16)
It is independent over time, which is rarely possible in the real longitudinal data.
Since in many known scenarios the event rate increases or decreases over time. In
most cases it can be used as the reference distribution to compare it with other dis-
tributions in modelling time to event data.
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Weibull distribution
The common form of the Weibull distribution is the two parameter Weibull distri-
bution; γ which is known as the parameter that gives shape to the distribution and
λ is the scale parameter. The survival distribution can be written as.
S(t) = e−λt
γ
(2.17)
and hence
h0(t) = γλt
γ−1 (2.18)
As explained in Table 2.1 γ = 1 the distribution will reduced to exponential distri-
bution with only scale parameter λ.
Table 2.1: Different shape of hazard rate
Values of γ Shape of h(t)
0 < γ < 1 exponential decay
γ = 1 constant hazard rate
γ > 2 exponential growth
γ = 2 straight line
Gompertz distribution
The Gompertz hazard function can also be used when the interest of the study is to
model the failure time: the survival function of the Gompertz can be written as:
S(t) = exp
(
λ0
θ
(1− eθt)
)
(2.19)
thus the hazard function can be written as:
h(t) = λ0e
θt (2.20)
where the domain of t is (0,∞) and the λ0 > 0, denotes the hazard rate that is
constant over time. The θ denotes the shape of hazard function, and if θ = 0 the
hazard function is reduce to that of exponential distribution, that makes the expo-
nential hazard function a special case of Gompertz Distribution; when θ < 0 as in
Weibull hazard function, it decrease monotonically; and when θ > 0 the hazard rate
increases. It can be noted that log(h(t)) of Gompertz distribution is a linear function
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of t.
Regression survival model
Non-parametric methods cannot control covariates. It is essential to have model for
covariates since the covariates have some advantages of explaining the condition
of survival time. The regression models are interested in modeling the data that
includes covariates. These are given:
h(t/X) = h0(t)η(X
Tβ) (2.21)
where the X is the vector of covariates, h0(t) is the baseline hazard, β is the vector
of regression coefficient and η(XTβ) is the link function. In the case where
η(XTβ) = exp(XTβ) > 0, ∀X, (2.22)
then equation 2.21 becomes
h(t/X) = h0(t) exp(X
Tβ) (2.23)
Kleinbaum (1998), Allison (2010) and Collett (2015) noted that when the baseline
hazard function is being specified, that model will be known as the parametric
model and the model takes the name of the assumed distribution. For example,
if h0(t) = λ then the regression model will be known as the exponential regression
model and it will be given as:
h(t/X) = λ exp(XTβ) (2.24)
if the baseline hazard function is assumed to be h0(t) = γλtγ−1 then the regression
model is called the Weibull regression model it will be given as :
h(t/X) = γλtγ−1 exp(XTβ) (2.25)
, and if the baseline hazard function is assumed to be h0(t) = λ0eθt, then the regres-
sion model is called the Gompertz regression model and is given as:
h(t/X) = λ0e
θt exp(XTβ) (2.26)
2.5 Summary
This chapter reviewed some concepts that are crucial in modeling survival time data
as it is the classic and the up to date way of modeling time to event data. An indi-
vidual may be interested in using some of these types of model based on the type
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of data and interest of the study. All these models are taken as essential methods on
analysing biostatistics problems. These are common methods that most authors use
to analyze the time to relapse data in epilepsy that our study is interested in.
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Chapter 3
Meta-analysis
Since survival analysis is widely used in analysing the time to a first seizure after an
epilepsy surgery. Our interest is in modelling time to relapse after epilespy surgery
using meta-analysis methods.
3.1 Introduction to meta-analysis
3.1.1 Limitations of single survival study
In scientific studies, the major aim is always to get better results with less error than
previous studies with similar objectives. This is done to ensure that bias and vari-
ability in the results is reduced (Cooper et al., 2009; Larry & Ingram, 1985; Cooper,
2015). Single studies are usually under-powered to be able to correctly detect the
effect of covariates (Egger et al., 2001). Sometimes if one focuses on just one popula-
tion, results can be questionable if the methodology was poor. It is natural to want
to look at more than one study of similar problem, in order to gain confidence in the
result.
3.1.2 Solution of single studies limitation
To increase results with certainty, the method of synthesizing studies with the same
problem, with a similar hypothesis, was developed (Cooper et al., 2009). The at-
tempt is to integrate the empirical research for the purpose of creating a generalized
result (Cooper et al., 2009). Cooper (2015) defines a combined studies as ”the study
that focuses on empirical studies and its goal is to summarize the previous studies
and come up with the conclusion from separated studies that address common hy-
potheses and its interest is to present the state of knowledge with the relation and
to highlight any crucial issue that was left unresolved ”. These methods were done
from the 17th century (Cooper et al., 2009) but the one that was first published by
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Pearson in 1904 was where he used the average to better the typical effect of inocu-
lation of other diseases. He used 5 separate samples for enteric fever and mortality
data (Simpson & Pearson, 1904).
3.1.3 Meta-analysis definition
In 1976, Glass (1976) introduced the word meta-analysis, where the term meta is a
prefix that means the abstraction from another concept that is used to finish the lat-
ter. According to Rothman et al. (2008), we can define meta-analysis as the analysis
of analyses that can be illustrated as the statistical analysis that combines the result
of multiple scientific studies (Ellis, 2010; Normand, 1999). What we can notice about
all those multiple scientific studies, they must have a common purpose of trying to
address a similar question (Rothman et al., 2008). Even if they have a common re-
search question but their findings will differ by a certain degree of error (the cause of
that might be because of the study methodology, different population, human error,
etc) (Ellis, 2010). The aims of the meta-analyst are to try to combine the findings of
these studies by using some statistical estimates methods to pool these results. Since
there are different degrees of errors, the meta-analyst will yield a weighted average
according to the uncertainty in each of the study, this will normally reflect the true
population of effect sizes more accurate than any of the individual’s estimates on
which is used Ellis (2010).
To perform the meta-analysis is very important in a research world to illustrate
that, let say the meta-analyst is interested in the clinical hypothesis and want to eval-
uate it, let say there are base from the published clinical trials articles, meta-analysis
can play an important role for summarizing the results of the quantitative literature.
Meta-analysis permits the objective assessing of the proof, which can result in reso-
lution of uncertainty and conflict. It will scale back the likelihood of false-negative
results and stop undue delays within the introduction of effective treatments into
clinical apply Arends (2006). It may also help in prior hypotheses relating to treat-
ment effects in subgroups of patients could also be tested with meta-analysis (Zou
et al., 2004).
Some authors have described meta-analyzes as research summaries of research
field which describe the general strength of the effect or variety of an item and the
statistical significance and the kind of moderator variables that one can predict the
strength of the object type (Cooper, 1989; Glass et al., 2009; Larry & Ingram, 1985;
Montgomery, 2000; Richard & Pillemer, 1984; Rosenthal, 1991). In additional Rosen-
thal & DiMatteo (2001) added that meta-analysis is not just a statistical process: be-
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cause of the methodology for systematically examining the body of research; the
formulation of hypothesis; the way it conducts on searching, establishing exclusion,
and inclusion criteria; for recording, and statistical synthesizing, and integrating the
effect sizes from these studies; it is a method of searching moderator and mediator
variables to explain effect of interest and on reporting the result.
These are some of the reasons why many scientists accepted meta-analysis and
used it on a complex studies (Higgins & Green, 2011)
i) Results are often generalized to a larger population..
ii) The precision and accuracy of estimates are often improved as additional infor-
mation is employed. This, in turn, could increase the statistical power to discover an
impact.
iii) Inconsistency of results between studies are often quantified and analyzed. for
example, will inconsistency arise from sampling error? Or ar the study results (par-
tially) caused by between-study heterogeneity?
iv) Hypothesis testing are often applied on summary estimates.
v) Moderators are often enclosed to elucidate variation between studies.
vi) The presence of publication bias are often investigated.
These are some of the advantages of meta-analysis (Deeks et al., 2008):
i) It assists people who are not familiar with statistics and also other researchers.
ii) It is accessible to anyone
iii) It provides some knowledge to policymakers
iv) It increases the certainty of the studies, that can increase research funding, and
also increases communication among researchers.
Presently meta-analysis is used in epidemiology and in evidence-based medicine
(Rothman et al., 2008). However, in medical treatment, it was only published in
1955. The more recent development on the analytical technique is on educational
research that was done by (Cooper, 1989; Glass et al., 2009; Larry & Ingram, 1985;
Montgomery, 2000; Richard & Pillemer, 1984; Rosenthal, 1991; Rosenthal & DiMat-
teo, 2001; Taghavi, 2014; Rücker et al., 2009) to mention a few. There are many de-
velopments in applications and techniques that make meta-analysis to be taken as
an advanced method of researching some interesting matters. That also increased
the interest of using meta-analysis in different fields of studies such as psychology,
social science, applied statistics, biostatistics, and ecology, to mention a few. It is
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because of these reasons that this study focuses on the meta-analysis of studies on
survival analysis of time until relapse after epilepsy surgery.
3.2 Effect sizes
The aim of meta-analysis is to search for studies and ask a new question based on
the result of those studies (DerSimonian & Laird, 1986; Ishak et al., 2007; Musekiwa
et al., 2016). Since meta-analysis is based on analyzing the findings of the different
studies it is essential to know the effect sizes. The effect size is the metric used to
compare two groups whose magnitude of treatment is required for deliberate inter-
vention (Ishak et al., 2007; Borenstein et al., 2009). The example of effect sizes might
be odds ratio or relative risk for binary outcomes, a mean difference for continuous
outcomes, or a hazard ratio for survival data. Borenstein et al. (2009) explain the
three major steps that must be followed before using effect sizes:
• The effect sizes should be comparable to one another across the study or measure
the same effects.
• It should be computable from the source that is reported.
• It should have good technical properties.
The question that is important in presenting the effect sizes is: there is any homo-
geneity across the studies (Normand, 1999)? If there is, then the fixed effect model
is the best model that can be used to analyze the effect sizes; otherwise, the random
effect model can be used to analyse the effect sizes. The main assumption of a fixed-
effect model is that one true effect sizes across all studies and observed effect sizes
will only vary because of the random error in each study (Borenstein et al., 2009;
Normand, 1999; DerSimonian & Laird, 1986), that is within-study variation. Since
there might be a difference between studies due to sample size and level of sam-
pling error, DerSimonian & Laird (1986) proposed another method of dealing with
this issue of variation. The assumption that is made about the variation will allow
the variation within a study and variation between studies. This model is called a
random effect model (DerSimonian & Laird, 1986).
The goal of synthesizing studies is not only to obtain the summary effect but also
to make sense of the effect pattern. This can be achieved by understanding the con-
sistency. If there is any, we consider the right implications for those cases. To under-
stand if there is evidence of variation we need to know the exact value of variance,
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the substantive implication of heterogeneity and the proportion of the observed dis-
persion (Borenstein et al., 2009). This will be done by identifying and quantifying
heterogeneity, using the test of significant, Q-test, to test if there is any heterogeneity
between the studies; estimating the variance between the studies, and estimating the
proportion of variation among the studies using the I2 − test. If it is large, the best
option is to use meta-analysis regression to analyze the effects (Normand, 1999).
3.3 Statistical methods of meta-analyisis
Suppose that in all included studies, the survival function is given or observed from
the Kaplan-Meier curve with their variance for each and every different time point
that each of the studies was analyzed. Using the survival function as the effect sizes,
it can be represented in terms of the Table 3.1.
Table 3.1: The survival proportion for each time point per each study
Study Survival endpoints
1 S1(t1) S1(t2) .... S1(tj) .... S1(tJ)
2 S2(t1) S2(t2) .... S2(tj) .... S2(tJ)
.
.
.
i Si(t1) Si(t2) .... Si(tj) .... Si(tJ)
.
.
.
N SN (t1) SN (t2) .... SN (tj) .... SN (tJ)
Table 3.1 can be interpreted as the proportion of survival of J pre-determined time
points for N independent studies. Si(tj) indicates the survival proportion for study
i at time tj .
The study pooled the survival proportion for each endpoint separately, and on
each of these time points, the classical methods can be applied.This is taken as the
easiest way to the survival data.
3.3.1 Estimation of survival proportion variance from confidence interval
In most cases, the studies that may be included may not present the survival pro-
portion variance, but they may present the confidence intervals for each survival
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proportion on that time point, but we can be able to estimate variance using the con-
fidence interval by Parmar et al. (1998) method. This can be used to estimate the
variance indirectly. If the (1 − α)% confidence interval is given for study i for each
time point j, the variance can be estimated by:
var(Sij) =
[
UpperCLij − LowerCLij
2φ−1(1− αi2 )
]2
(3.1)
where the UpperCLij and LowerCLij are the upper and lower limits of confidence
interval for Sij in study i on time point j, and φ
−1(1− αi2 ) is the cumulative standard
normal distribution for a given αi. Parmar et al. (1998) suggested that the confidence
must be used in the level of significance figure to allow for reliable accuracy.
3.3.2 Univariate meta-analysis
Without loss of generality assume that the effect sizes of interest is approximately
normal distributed. Let Yi be the observed outcome in the ith study. Where obser-
vations were done for each and every time point in the study (Parmar et al., 1998),
Yi ∼ N(θi, σ2i ), where the θi, denotes the mean and σ2i , denotes the variance in each
of the studies, then a general linear mixed model for study i can be given as:
Yi = θi + εi (3.2)
where εi is the random error and is assumed to be independent and normal dis-
tributed εi ∼ N(0, σ2i ), where σ2i is the variance (so that means it is assumed to be
known) and Yi is the effect size.
Fixed effect model meta-analysis
Under the assumption that all the factors that influence the survival proportion is the
same in all studies and therefore the true effect is the same and can be denoted by
θ, in this case, this can be modeled using the fixed effect model. It follows that the
observed effect sizes vary from one study to the next only because of the random
error inherent in each study and this is called within study variance (Borenstein
et al., 2009; Larry & Ingram, 1985).
The fixed effect model has the assumption that there is a true effect θ that is com-
mon in all studies (Borenstein et al., 2009), the only thing that differs is the variance
within each study. Generally the model is given as:
Yi = θ + εi (3.3)
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where θ and εi are the true effect size and random error respectively. Let us assume
that the observed effect sizes is normal distributed that is Yi ∼ N(θ, σ2i ) since this is
true εi ∼ N(0, σ2i ). It can be noted that even though the true underlying effect size
is the same across the studies Yi are not identically distributed because the random
error variance are not the same across studies. The maximum likelihood parameter
estimation of θ given σ2i is based on the following likelihood equation (Normand,
1999; Pigott, 2012; Borenstein et al., 2009):
f(y1, y2, ....yk|θ, σ2i ) =
k∏
i=1
1
σi
√
2π
exp
{
− 1
2σ2i
(yi − θ)2
}
= L(θ) (3.4)
then the log likelihood can be written as:
l(θ) = −k
2
log 2π−
k∑
i=1
log σ2i−
k∑
i=1
1
2σ2i
(yi − θ)2 (3.5)
assuming the σ2i known we will just only estimate the θ by maximizing log likeli-
hood with respect to θ and get θ̂ as
θ̂ =
∑k
i=1WiYi∑k
i=1Wi
(3.6)
where Wi is the weight given by the inverse of the study variance in fixed effect
meta-analysis that can be computed as:
Wi =
1
σ̂i
2 (3.7)
where σ̂i2 is the within study variance estimate for study i.
Thus θ̂ can be interpreted as a weight average of the effect sizes , and the variance of
θ̂ given by:
V̂ (θ̂) =
1∑k
i=1Wi
(3.8)
Then the standard error (SE) is the square root of summary variance.
SE θ̂ =
√
V̂ (θ̂) (3.9)
The confidence interval (CI) of the summary effect can be estimated using equation
3.9 as the SE and a given level of significant value and is given by.
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θ̂ ± zα
2
× SE θ̂ (3.10)
where from the standard normal distribution we use the convention that P (Z >
za) = a.
To test if the true effect sizes is zero, the Z-test is used
Z =
θ̂
SE θ̂
(3.11)
For one tailed the P-value is
P = 1− φ(zα) (3.12)
and for two tailed test the P-value is
P = 2
(
1− φ(zα
2
)) (3.13)
where φ (z) is the standard normal cumulative distribution.
Random effect meta-analysis
In a random effects meta-analysis model, we assume there might be different under-
lying effect sizes across the studies (DerSimonian & Laird, 1986) which may cause
the variation in the magnitude of the effect. It is assumed that the sample sizes are
not infinite and that the mean sample error is not zero (Borenstein et al., 2009). Sup-
pose the true effect for each study i is θi, then the observed effect sizes for each study
will be less than or greater than θi.
If we assume the normal distribution curve, the distance between the overall mean
and the observed effect sizes in any given study will consist of two distinct parts: the
true variation in effect sizes (ξi) and the sampling error (εi). The observed effect sizes,
Yi, will be model as for any study given by the pooled mean, the variation of the
study’s true effect from the pooled mean and the variation of the study’s observed
effect sizes from the true effect sizes that is given as:
Yi = µ+ ξi + εi (3.14)
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The aim of the random effect meta-analysis is still on estimating the overall weighted
mean and overall variance as we did in meta-analysis fixed effect model before.
Where the weighted mean can be estimated using the similar technique as one in
equation 3.6 the only difference will be that now we include the variation in between
studies, that we can call τ2. Then from this, there is a need of estimating the param-
eter of variance-between studies τ2 using the methods of moments as proposed by
DerSimonian & Laird (1986). It can be computed as follows: (in this study we will
be using T 2 as the estimate of τ2),
T 2 =
Q− df
C
(3.15)
where,
Q =
k∑
i=1
WiYi −
(
∑k
i=1WiYi)
2∑k
i=1Wi
(3.16)
and
df = k − 1,
where k, is the number of studies that will be included in the analysis, andC is given
by:
C =
k∑
i=1
Wi −
∑k
i=1W
2∑k
i=1Wi
. (3.17)
This estimation comes from the fact that expectation of Q is given as:
E(Q) = (k − 1) + (
k∑
i=1
Wi −
∑k
i=1W
2∑k
i=1Wi
)τ2 (3.18)
and it gives the estimates of:
τ̂2 = max
(
0,
Q− (k − 1)
C
)
(3.19)
Then we can compute the summary mean effect sizes by first starting as to note that.
W ∗i =
1
v∗i
(3.20)
where
v∗i = vyi + T
2 (3.21)
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and
θ̂∗ =
∑k
i=1W
∗
i Yi∑k
i=1W
∗
i
. (3.22)
Then the summary variance is the reciprocal of the sum of weights,
Vθ̂∗=
1∑k
i=1W
∗
i
(3.23)
and the SE is the square root of equation 3.23
SE θ̂∗=
√
Vθ̂∗ (3.24)
then the confidence interval may be computed as follows:
θ̂∗ ± zα
2
× SE θ̂∗ . (3.25)
If we need to test the null hypothesis that say the mean effect is zero the z-test statis-
tics is given by:
Z∗ =
θ̂∗
SE θ̂∗
. (3.26)
The one tailed the P-value that is based on a specific significant level is
P ∗ = 1− φ (± |z∗ α |) (3.27)
and the two tailed test P-value is,
P ∗ = 2 (1− φ (|z∗α|)) (3.28)
where, φ (z) is the standard normal cumulative distribution.
3.3.3 Heterogeneity and dispersion proportion
The researchers should not only focus on knowing the summary of effect sizes, but
it is also important to have information about the consistency and variation of ef-
fect sizes between the studies and consider the right method for that specific case
(Borenstein et al., 2009). According to Cooper (2015) and Borenstein et al. (2009)
the researchers suppose to ask the following questions when they analyse the meta-
analysis study: Is there evidence of heterogeneity? How big is the variance between
the studies? What is the real proportion of observed variation?
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It is known that it is rarely case to have the same observed effect sizes; because
of variation between studies there will be two causes of variation: heterogeneity of
studies and random error (Borenstein et al., 2009). According to Borenstein et al.
(2009); Pigott (2012) and Normand (1999) there are three steps to follow when deal-
ing with the different sources of variability:
i)computing the total amount of study to study variation;
ii) to estimate how much the observed effect size would be expected to vary from
each other if the true effect sizes was actually the same in all studies;
iii) the heterogeneity of studies.
The Q test statistic (Cochran Test) is used and it is sensitive to the ratio of the ob-
served variance to the within-study error.
Q =
k∑
i=1
Wi(Yi − θ̂)2 (3.29)
where the Wi is the weight of study i, Yi is the observe effect sizes of study i, θ̂ is
the pool effect, and k is the number of studies included in the study. Equation 3.29
can be explained as the dispersion of each effect size from the pooled mean, then
square it, weighted by the inverse-variance for each study i, and summing up all the
studies to yield the weighted sum of squares (WSS), Q (Borenstein et al., 2009). It
can be noted that metrics of effect sizes have no impact in Q.
If we need to know the expected value of Q, on the assumption that there is a true
common effect (that means the studies share the common effect sizes) and the within
study-variance is the only cause of variation in the studies. SinceQ does not depend
on metrics of effect sizes, the expected value depends on degree of freedom (df).
df = k − 1 (3.30)
Now the study has observed Q (the total dispersion), and the expected Q or excess
dispersion, also called the excess variation is given by.
Q− df (3.31)
The next step is to test the assumption of homogeneity in effect sizes. The first ques-
tion is whether there is any significant of heterogeneity in effect sizes, hence the
statistic Q will be used to address the question. Under the null hypothesis that the
meta-analyst will want to test is that the studies share a common effect size hence Q
will follow central chi-square (chi2) distribution with df , of k− 1. So we can report a
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p−value for any observed Q values. Rejecting the null hypothesis at a given level of
significance says 5% leads to the conclusion that the studies do not share a common
effect size. The purpose of the test is to assess the variability of the null hypothe-
sis and not to estimate the magnitude of the true dispersion (Borenstein et al., 2009;
Normand, 1999).
According to (Borenstein et al., 2009) we can estimate τ2 , the variance of between
effect sizes using the DerSimonian & Laird (1986) (DL) Method. It is impossible to
measure it directly, we can estimate it using observed effect sizes. To illustrate this,
we start with the excess variation in equation 3.31 which represents the dispersion
in actual effect sizes on a standardized scale; and we divide by quantity C, which is
defined on equation 3.15 which has the effect of setting the ratio back to its original
estimate and also making it an average rather than a sum of squared deviation. This
means it resulting to statistics T 2 has the same metrics as the effect sizes, and it also
shows the absolute amount of variation in that scale, if T 2 = 0 , Q < df , but if
Q > df (it can be noted that T 2 cannot be negative) then if T 2 is positive and it is
based on two factors: first is the amount of excess variation, and second the metrics
of the effect sizes index. Note T is written in the scale of the effect sizes but T 2 is not.
Like standard deviation in the primary study, the T can be used to show how the
effect sizes distribution about the mean. We can conclude that T allows us to talk
about the substantive importance of the dispersion about the mean effect sizes.
For the case of researching the proportion of the observed effect sizes reflecting
the real difference in effect sizes, the researchers used I2 statistics that was proposed
by Higgins et al. (2003), to reflect this proportion, that could serve as a kind of signal-
to-noise ratio,
I2 =
(
Q− df
Q
)
× 100% (3.32)
This is the ratio of excess variation to total dispersion. One can note that I2 statis-
tic is an explanatory statistics not an estimate of any quantity (Borenstein et al.,
2009). Since I2 shows the size of intersect of confidence intervals, which can be
noted that does not show any exact location or outspread of the true effect sizes, it
can be viewed as a measure of inconsistency across the findings of the studies and
not as the measure of real variation across the underlying true effect size (Higgins
et al., 2003; Borenstein et al., 2009). The I2 index give us the idea of the amount of
dispersion on a relative scale; we can say I2 ranged from 0 − 100% and it can be
noted that if we get I2 equal to negative percentage will put it as 0 that means there
is nothing that can be explained with the observed heterogeneity as if I2 is low, near-
zero then there is nothing that can be explained about the studies variance; but if I2
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is high, then we can speculate about the reasons for the variance and also possibly
apply a technique such as a subgroup analysis or meta-regression to try and explain
it (Borenstein et al., 2009; Pigott, 2012). Higgins et al. (2003) provided benchmarks
for I2; they suggested values of the order of 25%, 50% and 75% as indicative of low,
moderate and high variability respectively.
3.3.4 Computing the power in random effect meta-analysis for mean ef-
fect size
According to (Borenstein et al., 2009; Hedges & Pigott, 2001; Pigott, 2012) the power
analysis can be computed using the following approach. An approximate signifi-
cance test that the mean µ differs from a predefined constant µ0 assuming the nor-
mal distribution when the null is true can be used. If the null is not true then Z∗ the
standardized statistics has a standard normal distribution with the mean
λ∗ =
µ.− µ0√
v∗.
, (3.33)
and if the null is rejected the power of the one tailed test is given by
P = 1− φ (Zα − λ∗) , (3.34)
φ(x) is the standard normally cumulative distribution function.
The power of two tailed test can be computed, if the null is not true, which will
happen if |Z∗| > Zα
2
, which is similar to Z∗ > zα
2
or if Z∗ < −zα
2
, then the power
for the test case can be given as
P = 1−
(
φ
(
zα
2
− λ∗
)
+ φ
(
−zα
2
− λ∗
))
. (3.35)
The equations 3.34 and 3.35 are not useful if the λ∗ is not known, which depend on
µ; the within study variance, vi for v1, v2, . . . . . . . . . ., vk (we only assume that for
all studies we have a common v (variance) (if v’s are not the same Hedges & Pigott
(2001) gives more details on how that issue must be handled) ; and between studies
variance. As in homogeneity test in fixed effect case, if the within study variance is
common we used the convention that was suggested by Schmidt & Hunter (1979).
Hedges & Pigott (2001) proposed the approach when we dealing with heterogeneity,
for small degree of heterogeneity τ2 = 0.33v = v3 must be used , for medium degree
τ2 = 0.67v = 2v3 must be used , and for lager degree τ
2 = v must be used. Then
we can take all within study variance values as approximated to be common and
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compute as:
v∗. =
v + τ2
k
(3.36)
If the within study variance is not common, then the right hand side of equation 3.36
will be strictly larger than the left hand side of an identical within study variance.
This will lead to underestimate of the statistical power.
There are several things that must be noted when performing the significance test,
and power analysis test. The first is that the significance test is done when the study
is already being collected and analysed; while the power analysis test is performed
before the study analysis. It depends on a projected value rather than performed.
Borenstein et al. (2009) mention that if the effect sizes is lower the power will be
lower than the power of a larger effect sizes.
3.4 The publication bias
Publication bias occurs because in meta-analysis there is an inclusion criterion that
the meta-analyst set out to be met but if it was not possible to do so, then there would
be more chances of including studies with significant results (since there is more
chance of publication of papers with significance result)(Egger et al., 1997; Sterne
et al., 2004; Harbord et al., 2009). Ultimately this means the analysis will be biased
against studies that were not published or the non-significant studies (since these
studies will lack the chance of being included in the review analysis). Because we
cannot be sure whether the meta-analysis is free of publication bias or not, an analyst
needs to use the methods that can answer these questions: is there evidence of any
bias? Is it doable that the whole impact is an unit of bias? and the way abundant of
an effect may the bias have?
The problem might also be the small study effect which may lead to some studies
not being published. Harbord et al. (2009) mention these three condition:
• the large studies are more likely to be published, where statistical significance has
not been considered
• moderate-sized studies are at risk of being lost
• small studies have a high risk of being lost.
These three conditions show that publication bias is expected to increase as the sam-
ple size decreases.
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A funnel plot can be used to test for any bias in the data especially publication bias.
The funnel plot is a visual tool to aid in detecting publication bias in meta-analysis.
Basically it is a scatter plot of the effect sizes (X-axis) from each study against the
sample size or standard error (Y-axis) (Sterne et al., 2004). Visually, when the sample
sizes are on the Y-axis, large studies appear toward the top of a graph and cluster
around the mean effect size; while smaller studies appear at the bottom of a graph,
thus the plot helps to identify how asymmetry the graph is. In the absence of publi-
cation bias, the funnel plot will be symmetric; and in the presence of publication bias
the plot is expected to follow the model, with symmetry at the top,a few of studies
missing within the middle and additional studies missing close to the lowest. If the
direction of the effect sizes is towards the right, then near the bottom of the plot we
expect a gap on the left where the non-significant of studies should have been if we
had been able to locate them, also the converse direction is true (Sterne et al., 2004).
It can be noticed on the funnel plot that the source of asymmetry is not only bias
but other sources of asymmetry can be the heterogeneity of effect sizes, data irregu-
larities, artifact or chance (Egger et al., 1997; Sterne et al., 2004). In terms of hetero-
geneity, the meta-regression can be used to deal with that matter.
It is believed that small sample sizes cause overestimation of effect sizes (Harbord
et al., 2009); might increase the type II error. So, for a meta-analysis contains which
involves small studies, the results should be interpreted with caution, altogether
with discussion and conclusion (Harbord et al., 2009; Egger et al., 1997).
3.5 Dependence of effect sizes between time points
If we know that in each of the included studies, effect sizes were observed over time
for each time point, we are more interested in capturing the correlations between
effect sizes within a study that are longitudinally observed or recorded. That can
be done by modelling the correlation of serial of effect sizes within the study. Such
data leads to the meta-analysis of longitudinal studies, which can be defined as the
combination of effect sizes that were measured at pre-determined time points during
the course of follow up (Ishak et al., 2007). In most cases, meta-analysis studies are
reporting effect sizes that are reported at the same time point (for example from the
time-origin, at 1 month, 12 months, and 24 months, etc) like in the case of Ishak
et al. (2007) and Musekiwa et al. (2016)) and in many trials. If that is not the case
there must be more consideration in terms of multiples parameters, since these are
inherently correlated (Musekiwa et al., 2016).
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There are pertain time points for some group of patients that are reported in each
study over a period of time and there are correlations to be investigated, the effect
of these time points. Arends (2006) and Ishak et al. (2007) stated that if these corre-
lations are ignored, estimates can lead to an overestimated variance of the summary
effect sizes and biased estimates. Some of the published authors avoid the corre-
lation in different time points by carrying out a meta-analysis in each time point
(Trikalinos & Olkin, 2012), but for more refined and unified analysis methods to
handle correlated effect sizes in the meta-analysis have been developed and well-
developed software to handle such cases are now available in much statistical soft-
ware (Olkin & Gleser, 2009; Dear, 1994).
suppose there are k studies, denoted by i = 1, 2, ...., k and T denotes the follow-
up time. The data that we consider is time to event data. Let us say in study i
there are T effects sizes recorded at times t = 1, 2, ...T , that are contained in an ef-
fect sizes T -dimensional vector yi = (yi1, yi2, ...., yit, ...., yiT ). In survival analysis,
the effect sizes are usually hazard ratios estimated at the T time points. Each yit is
estimated with a sample variance σ2ij , and the correlation between pairs outcomes
(tt′) within each study is corr(yit, yit′) = ρitt′ . The approach is to extracts informa-
tion that is used, by first estimating the vector yi and corresponding variances of
Si = (σ
2
i1, σ
2
i2, ..., σ
2
iT ). As explained in the previous section, in a univariate meta-
analysis approach, especially in the random effects model, the overall variation was
within and between study variation. In a multivariate setting, the same partitioning
of the variance holds where it not that different since now the overall variation is
still between those two within and between study variation but in addition it also
includes within and between study correlations (Mavridis & Salanti, 2013).
3.5.1 Models for outcomes in multiple time-points meta analysis
For the k studies, i = 1, 2, ..., k that are observed at two time points each, we can
estimate two (or more) effect sizes for each study. This means that for each study, i,
the estimated effect sizes are Yi = (Yi1, Yi2) such that Yit = x′itβ + z
′
itδi + εit, where
xit is a l × 1 design vector for the l fixed effects. It correspond to β which is a l × 1
vector co-efficients. zit is a design vector, of dimension q × 1, of a random effects δi.
The effect εit is the residual term for the effect sizes Yit, the σ2it is the estimated of
within study variance in time-point t. Let us consider a random effect model where
the between study variance associated with effect size j is denoted by τ2j , which
is the heterogeneity parameter for effect size j. The variance-co-variance structure
is the sum of within and between study variation. The effect sizes are assumed to
follow a multivariate normal (MVN) distribution as:
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(
Yi1
Yi2
)
vMVN
( (
µ1
µ2
)
,
[
σ2i1+τ
2
1 ρiσi1σi2+ρττ1τ2
ρiσi1σi2+ρττ1τ2 σ
2
i2+τ
2
2
] )
(3.37)
The model can be written as the general linear mixed model (Laird & Ware, 1982),
Yi = Xiβ + ziδi + εi (3.38)
where Xi is the T×(l) matrix with the observed covariates values for each of the
studies and β the vector of l co-efficients, where the baseline is not included. Where
zi is a design matrix for the random effect of dimension T × q and δi is a vector of
a random effect associated with the study i. It is assumed that δi follows an MVN
distribution that is δi ∼ MVN(0,∆), where ∆ is the between study variance-co-
variance matrix involving the τ2i and the unknown correlation parameter ρτ(jj′))
and the structure is given as:
∆ =

τ21 . . . ρτ(1,q)τ1τq
...
. . .
...
ρτ(1,q)τ1τq . . . τ
2
q
 (3.39)
and εi is a vector of random sampling errors associated with the study i which is
independent of δi and it is assumed to that εi ∼MVN(0, Si). It can easily be shown
that marginally yi ∼MVN(Xiβ,V) where V = ∆+Si. It is noted that the structure
of V may differ depending on the main interest of the model.
3.5.2 Fitting the multivariate meta-analysis
n this subsection, we are going to describe only the random effect model since the
fixed effect is taken as a special case where the heterogeneity is equal to zero (∆ = 0)
(Mavridis & Salanti, 2013). the main interest is on the effect sizes, the vector of
summary effect for T outcomes ( for simplicity let us make Xiβ = µ) The focus of
study interest is only on the random-effects model; the fixed effect model is taken as
a special case where the heterogeneity is zero (Mavridis & Salanti, 2013). The main
interest is on the effect sizes, the vector of the summary effects for the T outcomes
(for this case lets us make µ = xitβ; and the uncertainty which can be estimated by
the T × T variance-covariance matrix V and ∆.
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Likelihood
If we assume that all studies are independent experiments, as suggested by Mavridis
& Salanti (2013), the log-likelihood to estimate the model parameter can be given as:
L ≈ −1
2
Σni=1log|∆+Si| −
1
2
Σni=1ε
′
i(∆+Si)
−1εi
Then according to Ishak et al. (2007); Trikalinos & Olkin (2012); Mavridis & Salanti
(2013) and Steel & Kammeyer-Mueller (2008) stated that this likelihood can be max-
imized by a numerical iteration methods using the expectation-maximization nu-
merical, Newton-Raphson or Fisher scoring algorithms subject to restriction that ∆
is positive semi-definite. Although this method is good on estimating the estimates
of interest, it can be computationally intensive and time demanding.
Maximum likelihood estimates
Assuming that all studies report the same outcomes and there are no missing values,
then the summary estimates can be obtained by maximizing the likelihood:
µ̂ =
(
Σni=1(∆̂+Si)
−1
)−1 (
(Σni=1(∆̂+Si)
−1)y
)
(3.40)
the summary estimates are approximately normally distributed with the variance-
covariance matrix:
V̂ = (Σni=1(∆̂+Si)
−1)−1 (3.41)
The parameter µ and ∆ are estimated iteratively in expectation-maximization nu-
merically algorithm with equation 3.40 being one of the 2 steps. An approximation
(1−α)100% confidence interval can be obtained for µ̂j as µ̂j ± zα
2
√
V̂jj , where V̂jj is
the j-diagonal element of the V̂ matrix. The alternative method that can be used is
the quantile method based on the t-distribution (Mavridis & Salanti, 2013).
In case of missing outcomes 3.40 cannot be used directly to compute the estimates
as the dimension of matrix ∆ and Si will not be the same across studies (Mavridis
& Salanti, 2013). This issue can be resolved by imputing those entries in the covari-
ance matrix by allocating very large within-study variance to the missing outcomes
and zero within-study correlation, ensuring that missing outcomes contribute neg-
ligible weight and information (Mavridis & Salanti, 2013; Trikalinos & Olkin, 2012)
in the estimation of the combined effect sizes. Most of the difficulties will lie in the
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estimation of between-study covariance matrix parameter ∆, which will be used in
summary effect sizes estimation in equation 3.40.
In maximum likelihood estimation theory, the restricted maximum likelihood (REML)
play an important role in producing unbiased estimate of variance and covariance
parameter matrix in mixed models (Mavridis & Salanti, 2013). In fact REML has
the capacity to deal with unbalanced data by design or that due to missing observa-
tions. In this case it can also be used to estimate the covariance matrix ∆ in the case
of meta-analysis. The modified log-likelihood is given by:
RL ≈ L− 1
2
∣∣∣∣∣
n∑
i=1
(∆̂+Si)
−1
∣∣∣∣∣ (3.42)
Using Cholesky decomposition, ∆ can be ensured to be positive definite when max-
imizing the likelihood function, then to compute µ and V, ∆̂ can be used (Mavridis
& Salanti, 2013).
Methods of moment
Method of moment estimation is another approach that can be used to estimate µ
and V, for that reason the µ̂ and V̂ will still be defined as in equation 3.40 and 3.41,
but ∆ is estimated by employing a multivariate extension of the Q ∼ statistic and
the method of moments was extended by Jackson et al. (2010) from DerSimonian &
Laird (1986) method of moments
Qj =
n∑
i=1
Wij(Yij − Yj)2 (3.43)
where Yj is weighted mean of Yij across studies and the weights are
Wij =
1
σ2ij
Then on estimating the expectation, the Qj that will include estimation of τj and µj
is estimated as a weighted average with weights
W ∗ij =
1
σ2ij+τ
2
j
.
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When the multivariate approach will be similar to that of univariate. We can have p
outcomes and Q is a matrix given by:
Q =
 Q11 ... Q1p. Qjj′ .
Qp1 ... Qpq
 (3.44)
where this element denotesQjj =
∑
iεNjj
(Yij−Yj)2
σ2ij
andQjj′ =
∑
iεN
jj
′
(Yij− ¯Yjj′ )(Yij−Y j′j)
σjjσjj′
.
In this case Njj denotes the set of studies where only outcome j is reported and Njj′
is the set of studies where both outcomes j and j′ are reported. Yj is the weighted
average of outcomes over the studies reporting only the outcome j (with the weights
Wij across studies) and Y j′j is the weighted average of outcomes over the studies
that report the outcomes of j and j′ (with the weights
√
WijWij′ across studies). If
there are missing values, they can be, handled by replacing them with arbitrary val-
ues with large within-study variance and summing all studies (Mavridis & Salanti,
2013; Jackson et al., 2010).
Jackson et al. (2010) show how to estimate ∆, by showing that it can be estimated
by equating the expected value of Q, E(Q) = E. It can be shown that the diagonal
Ejj are function of σij and τj , given as:
E(jj) = E(Q(j,j)) = (nij − 1) +
(∑
iεNjj
Wij −
∑
iεNjj
W 2ij∑
iεNjj
Wij
)
τ2j (3.45)
where nij is the number of studies included in the study, and Wij = 1σ2ij
. This is
a linear function of unknown between study variance τ2j , hence by equating Ejj =
E(Q(jj)) and we can solve the linear equation to estimate τ2j in a similar way as
in univariate case. Off-diagonal elements Ejj′ are a function of σij , σij′ , τj , τj′ , ρτ ,
which is given as:
E(jj′ ) = E(j′j) = a+ bρττjτj′ (3.46)
where
a = ΣiεN
jj
′ ρi−
∑
iεNjj′
ρi
σijσij′∑
iεNjj′
1
σijσij′
(3.47)
,
b =
∑
iεN
jj
′
1
σijσij′
−
∑
iεN
jj
′
1
σ2ijσij′
2∑
iεN
jj
′
1
σijσij′
(3.48)
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. Additional E(jj′) = E(j′j) is a linear function of the between studies covariance
ρττjτj′ , hence this can also be estimated from equation 3.46. Thus all the elements
of ∆ can be estimated. However the method does not necessarily yield estimates of
∆ that are positive semi-definite. Jackson et al. (2010) give more details on how to
handle that matter.
The advantage of this method is that there is no numerical maximization or it-
eration and because of that it saves time (Mavridis & Salanti, 2013). The other ad-
vantage is that the estimate of between study variance can be estimated without the
assumption of normality (Jackson et al., 2010).
3.6 Meta analysis of survival curve
In the interest of doing pooling of survival time analysis methods using meta-analysis,
there are some methods that were proposed. We look to a few of those that we
think are essential for present work. Dear (1994) proposed the method which uses
the fixed effects meta-analysis model using the iterative generalized least squares at
multiple time-points(this method used the multivariate methods). In 1998 Parmar
et al. (1998) gave a tutorial (basic approach on how to handle time to event meta-
analysis) on how to extract the time to event data and showed how to analyse it.
Arends et al. (2008) extended the Dear’s methods to random-effect meta-analysis at
multiple time points. It can be noted that most of these methods that had been pro-
posed on dealing with the time to event meta-analysis have data that contain two
arms of treatment.
For data that only has one arm treatment (single population), Combescure et al.
(2014) proposed the method that can handle that. In this section we will briefly
explain how it can be applied.
Let us start by explaining the basic method of survival probability, which is to
use product limits estimator to analyze individual data. This is done by taking the
survival probability at time tj that is denoted by S(tj) as the product of conditional
survival probability till interested time tj (Collett, 2015), given as:
S(tj) = p1p2 · · · pj (3.49)
where pi for i = 1, 2, ..., j is the probability that individuals was alive at time ti−1
and is still alive at time ti.
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Since in the current study there is a need for estimating survival probability, a
similar approach as proposed by Combescure et al. (2014) will be used. To estimate
the conditional survival probability we are going to use survival probability that will
be extracted from published studies at each time point (t1, t2, ..., tJ) for each study
i. The conditional probability will be pooled using the common method in a meta-
analysis that is the fixed-effect model and random effect model. Then the summary
survival probability can be obtained by substituting the pooled estimates to equation
3.49 (Combescure et al., 2014; Jackson et al., 2010). Combescure et al. (2014) stated
the advantage of using the Kaplan-Meier estimator is that the right-censored event
is included in the estimates of pi, thus also in the estimates of summary survival
probability.
According to Combescure et al. (2014) let the extracted survival probability from
published studies be denoted by Ŝk(tj), where k represent the included studies and
j range from 0 to JK . Let the survival probability at the origin be 1 that is (Sk(t0) =
1). JK depends on the length of follow-up in study k which vary across included
studies. It will be like J = max {Jk}which is taken as last time-point in the included
studies. Let us assume the number at risk during interval [tj−1; tj ] is denoted by
Nkj assuming they are all known in all included studies at time tj . According to
Combescure et al. (2014) the number of patients at risk before the first time-point
is equal to number of patients included in study k (sample size). The number of
patients at risk before the second time point can be computed as follows: number
of patients at risk for (t1, t2) is equal to Nk × Ŝk1 = Nk2, which generally can be
calculated asNk×Ŝk(tj−1) = Nkj (Parmar et al., 1998; Pocock et al., 2002; Williamson
et al., 2002).
The conditional survival probability will be denoted by Pkj which is the probabil-
ity that patients that were seizure free at time tj−1 in the study k are still seizure free
at time tj . Pkj can be computed as:
Pkj =
Ŝk(tj)
Ŝk(tj−1)
, forj ≥ 1 (3.50)
Since by this approach we pool estimates using meta-analysis, this model assumed
that the estimates are normally distributed or the number of studies are sufficiently
large for central limit theorem. Then according to Combescure et al. (2014) there is
a need of transforming probability before pooling it. The best transformation in this
case is arcsine with continuity of 0.25 (Anscombe, 1948; Brown et al., 2010; Rücker
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et al., 2009). The arcsine transformed probability is given by :
π̂kj = arcsin
(√
NkjPkj + 0.25
Nkj + 0.5
)
(3.51)
It is then assumed the π̂kj is normally distributed with the variance of:
V̂ ar(π̂kj) = 0.25(Nkj + 0.5)
−1 (3.52)
It can be noted that the variance is estimated using the number of patients at risk at
time tj (if Nkj is large then a smaller variance than obtained when Nkj is small).
What can be noted for this correction method is that for a rare event or small sam-
ple size the normal approximation is not accurate. Since there is a vector of π̂kj in
study i, the vector can be denoted by π̂kj , and the covariance matrix of π̂k can be
denoted as Sk , it can be noted that the Sk is diagonal since the conditional survival
probabilities are not correlated and it should also be noted that the diagonal, within
variance can be estimated using equation 3.51. When the summary estimates are
also of interest these can be estimated using the random effect model. There will be
a need to estimate the between-study covariance matrix which will be denoted by ∆.
In the need of estimating the random effect model summary estimates the extended
DerSimonian & Laird (1986) method that was proposed by Jackson et al. (2010) will
play an important role. Since it is known that DerSimonian & Laird (1986) method
are approximately normally distributed, the method that was discussed under sub-
section 3.5.2 can be used. To estimate π̂ and V(π̂), equation 3.40 and equation 3.41
will be used too.
After this transformation is computed then the common method of pooling in
meta-analysis will be applied to pool π̂k and the confidence interval can be esti-
mated, also the test of heterogeneity can be done like common meta-analysis method.
After this method has been done the pooled conditional summary probability can be
computed from pooled π̂ using back-transformation:
P̂ = sin2(π̂) (3.53)
and the pooled survival probability is obtained by the product of conditional prob-
ability:
Ŝ(tj) = Π
j
s=1P̂s (3.54)
where j = 1, 2, ..., J denotes the time points, so we can use equation 3.52 to estimate
summary survival probability up to time tj and the confidence interval of time tj
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can be estimated by using delta method to get variance of pooled survival probabil-
ity. To get the variance we must first transform Ŝ(tj) using log transformation and
log(Ŝ(tj)) is assumed normal distribution then using Greenwood formula by apply-
ing delta method (Collett (2015)) (the delta method by Combescure et al. (2014) is
shown in Appendix 7.3).
3.7 Summary
This chapter generalized the meta-analysis methods of both fixed effect and random
effect meta-analysis, when the interest is on using the univariate or the multivariate
especially when the outcome of interest is measured over time (longitudinal meta-
analysis studies).These methods will play an important role in the next chapter when
we show how we combined the effect sizes of the studies that their interest was to
model the time to seizure relapse.
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Chapter 4
Systematic review
This chapter will show criteria that were used for the selection of studies, the ex-
traction of the data from those published studies and software that can be used to
meta-analyse the data.
4.1 Study selection
In this study, we used searched databases including the Google scholar, Medline and
Pubmed which played a key role in guiding the study to the different online journals
like ScienceDirect, Neurosurgery, Sage-pub, Brain, Epilepsia. We started searching
for published studies without putting limits on the range of years, but it seemed that
there were more studies conducted in recent years as medication and technology
advanced compared to the past three decades where treatment was difficult. We
then put the restriction from January 2000 to May 2017, a period of 17 years, since
these were the times when more developments in surgery, especially of sensitive
parts like the brain, became common (Ingram, 2013; Preul, 2005; Wickens, 2014).
The keywords that were important on searching for these published articles were:
long term effect after epilepsy surgery, epilepsy longitudinal studies using the sur-
vival analysis, epilepsy surgery, neurosurgery, temporal surgery and survival anal-
ysis in seizure outcome after the epilepsy surgery.
4.1.1 Eligibility criteria
The eligibility criteria were:
1) Studies that were published from January 2000 to May 2017.
2) Articles based on quantitative research results and following this study design:
cohort, case control and randomized controlled trial.
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3) Articles published in English.
4) All studies had to be peer reviewed in academic journals.
5) Longitudinal studies: they must be followed-up (at least 1 year) after surgery and
the analysis used survival statistics measurement (survival after surgery).
6) The study must be done on patients (human beings) that had gone for an epilepsy
surgery treatment.
7) In those articles the classification methods of being seizure free (epilepsy) must be
defined using the International League Against Epilepsy (ILAE) (Fisher et al., 2005;
Wieser et al., 2001) and/or Engel Classification.
Engel classification is used to classify postoperative outcomes for epilepsy surgery.
Engel (1993) proposed the Engel Epilepsy Surgery Outcome Scale, which has be-
come the standard when reporting results in the medical literature. It is defined in
four categories:
i) Engels class Ia is the first class; it consists of the patients who reported no seizure
after their surgery.
ii) Engels class Ib is the second class; it includes both seizure free patients and those
that experienced simple partial seizure or simple auras and neighbourhood seizure
and drug withdrawal seizure.
iii) Engels class II it consists of patients that were not seizure free but had a substan-
tial improvement, exhibiting only rare seizures.
iv) The forth subgroup, Engels III-IV, includes all patients with frequent seizures and
a truly unsatisfactory outcome.
In most studies, these post surgery classifications were identified by the quali-
fied neurologist and pathologist for each and every patient that was included in the
study (Fong et al., 2011; ?; McIntosh et al., 2004, 2012; Jeha et al., 2007; Berg et al.,
2006; Sarkis et al., 2012; Bulacio et al., 2012; Jehi et al., 2009; Elsharkawy et al., 2008;
Dupont et al., 2006; Ramesha et al., 2011; Paglioli et al., 2004; Bell et al., 2009; Mu
et al., 2014; Garcia Gracia et al., 2015; ?)
The interest in the current study was in finding the time to event (how long pa-
tients survive with seizure freedom after surgery), where event was seizure and time
was the period after surgery (which in most of the studies was measured in months,
if this was not true it was converted). Most included studies started with the pre-
operative patient evaluation, where an individual goes to electroencephalography
(EEG) and Magnetic resonance imaging (MRI) for brain electrical activities and brain
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lesion identification. Then after the surgery they did the post-operative evaluation,
where they use MRI to take the internal brain image. Then after this, the neurologist,
physicians and pathologist assessed each of the patients who were followed to check
for seizure freedom. If the seizures had occurred, the time of the event (seizure) was
recorded .
4.1.2 Search findings
As indicated in the flow chart in figure 4.1, this study only used the electronic search
of available database which yielded 211 citations using the key search words. We
carefully read the titles, abstracts and the studies that were not relevant were omit-
ted. Then 84 studies were screened longitudinal studies where each patient was
followed up over time. Thirty seven of them were excluded because they did not in-
clude the important points that were relevant for the study. The remaining 47 were
important for the study because they had the follow up of at least one year; long term
outcomes after epilepsy surgery were discussed; survival measurement was the out-
come of interest. These 47 studies were screened again, where the focus was on the
introduction, methods, and the results, respectively, to see if the primary studies
include those important criteria and the important statistical outcomes. After that,
only 16 studies remained that were included for meta-analysis. The essential point
for the included studies was that the survival curve must be clear(survival propor-
tion and time point). These 16 remaining studies were considered to be the best be-
cause they had a reasonable sample size, they used the survival analysis to calculate
the seizure freedom (where their event of interest was first time to seizure recurrence
post-operative). The focus was not that the survival proportion must be represented
with the standard error but we were more concerned, about how many patients
were at risk on particular time-points, then after that information was known, it was
possible to compute variance for each survival proportion. The studies were done
over time (longitudinal studies) at least one year of follow-up. In those studies, the
surgery was done on humans and recently (between 2000 and 2017).
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Figure 4.1 – A flow chart of the inclusion criteria
4.2 Summary of 16 studies (included)
Table 4.1 summarizes the information from 16 included the studies. It can be noted
that the studies have varied years of inclusion (2000 to 2015). It can also be noted that
most of those studies were done in developed countries (United State of America,
Australia, United Kingdom, France and Germany) and few were from developing
countries (1 in India and 2 from Brazil) which might give some problems in general-
izing the result to the whole world.
Most of the included studies have a large sample which will be good for estima-
tion. It can be noted that all included studies used survival analysis to analyze their
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4.3. Data extraction
data, where Kaplan-Meier was used to calculate the proportion of seizure freedom
over time and log-rank to compare survival proportion for different groups of in-
terest. In studies that used multivariable analysis, their best option was the Cox
proportional hazard model. To get the best variable that could be used in multivari-
ate analysis, one of these methods was used: Wilcoxon rank test, Chi-square and
Fisher’s exact test and the significance of these variables being examined measured
under 10% level of significance.
It seems that it will be difficult to do meta-analysis regression if heterogeneity
is present in this study to explain the variation since there are different significant
variables in each study. It can be noted that those studies that were done for surgery
with normal MRI lesion have higher chances of survival (Fong et al., 2011) compared
to not normal MRI lesional (McIntosh et al., 2004) when we ignore different timelines
of studies. It can also be noted that those studies that were done on a patient with
temporal lobe have higher chances of survival compare to others like frontal lobe
or extratemporal lobe (Fong et al., 2011; McIntosh et al., 2004, 2012). The significant
variables that appeared more than once were resection type, pre-operative or post-
operative spiking (Bulacio et al., 2012; Sarkis et al., 2012; Jehi et al., 2009; Jeha et al.,
2007). In some of the studies, there were no significant variables (McIntosh et al.,
2004).
4.3 Data extraction
We are interested in the sample sizes of those included studies together with survival
curve which help us to extract the survival proportion.
As it is indicated in Table 4.1 the number of patients in these studies ranged from
39-492. The follow-up time ranged from 6-180 months, but only one study had a
follow-up that lasted for 180 months (Hemb et al., 2013). We only have 6-time points
that were important for this study; 6, 12, 24, 36, 60, and 120 months. The reason for
choosing these time-points were:
1 although it seemed that the post-operative check-up of patients were done
monthly after surgery till 6 months, the 6 months seemed like an important
time point to the authors because they only started presenting the results on
this time point,
2 then the post-operative check-up was done yearly till 36 months.
3 After that, they did it after 24 months from 36 months of post-operative and at
last after 120 months (that is 10 years).
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Almost half of the studies end at 120 months of follow-up and the others ended at
60 months of follow-up.
It can be noted that there was no summary for 180 months since we cannot pool
the result for only one study. Elsharkawy et al. (2008) had three separate groups that
were done in different follow-up years (their main reason was to see, as time goes
on, whether there were improving on how they performed the operation) also on
different patients. The first group was followed from 1991 - 1995, the second group
from 1996 - 2000, and the third group from 2001 - 2005. Only 5 studies show how
many patients were at risk at particular time-points, especially the time points we
were interested in (Bell et al., 2009; Fong et al., 2011; Lowe et al., 2004; Elsharkawy
et al., 2008; Dupont et al., 2006). In the case where the number of at risk patients was
not given at the time points, the following formula was suggested by Combescure
et al. (2014) to determine at least patients:
Nij = NiSij−1 (4.1)
where Ni denoted the number of patients in the study i, Sij−1 denote the survival
proportion in study i at time point tj−1 and Nij is approximately the number of
patients in study i at time tj was used to calculate the number of risk patients at
our interested time-points. If the study showed the number of patients censored
between time point (tj−1, tj) then the number of risk patients would be subtracted
like in the study of Mu et al. (2014).
The estimates of survival curves for the included studies can be observed in Figure
4.2. It is clear that the study by (McIntosh et al., 2012) had the smallest estimates
across all time periods. Some studies had the survival estimates that do not start at
Sij(0 = 1). This indicates that some surgical treatment were not so successful.
4.3.1 Statistical software
To analyse the meta-analysis data some standard statistical software can be used. In
R the RMETA or METAFOR package can be used in SAS the PROCMIXED pro-
cedure, and in STATA, metan command can also be used. There are also software
that were made to analyse the meta-analysis data only like Comprehensive Meta-
Analysis (CMA) and RevMan to mention a few. To be specific, in this study, the R
version 3.2.2 of 2015 by the R Foundation for Statistical Computing was used to anal-
yse the data. The R software was chosen since it is freely available, it can be installed
on a personal computer without a key license and if the required package is installed
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Figure 4.2 – Survival curve
it can be run without internet. The RMETA and METAFOR package, developed by
Kovalchik (2013), will play an important role in modeling the data especially the
fixed and random models (using different approaches Dersmonian and laird meth-
ods, likelihood or restrict likelihood estimator to estimate between studies variance
(τ2)). These packages will also play a key role in the graphical approach to model
the funnel plot and forest plot which are important in interpreting the meta-analysis
result.
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Chapter 5
Univariate Analysis
In this chapter the univariate meta-analysis method was used to analyze the data
that was shown in Table 4.1; here the meta-analysis coefficients at each time-point
are modeled separately.
Since the assumption of the study was that we had included many studies, it was
possible to use the central limit theorem; that means we assume that the summarized
survival proportion is approximately normally distributed although we only have 18
studies. In the current application the survival proportion and variance of survival
proportion were observed in each study i over 6 time-points that is after month 6,
month 12, month 24, month 36, month 60 and month 120 (only 1 study, Hemb et al.
(2013) followed-up to 180 months but it was not possible to pool it).
5.1 Fixed effect meta-analysis
The summary of survival proportion was computed for study i in each separate
time-point (1, 2, 3, 4, 5 and 6). Our concern was only on the variation that was
caused by the random error (that may be the fault in methodology or the way of
collecting the data and so on in study i). All studies are assumed to have a common
effect. Here, we assume the studies are independent.
5.1.1 Results
In total, there were 2647 participants who underwent epilepsy surgery. In those
studies, the main focus was on the extratemporal lobe, temporal lobe and inferior
frontal lobe as the types of epilepsy that the surgery treatment might be useful in
treating. Since the interest of the study is the time to first seizure (relapse) post-
operation, the study is interested in those studies that measured the time of relapse
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using the survival analysis that has good properties of handling the time to event
data. We observed survival proportion in a longitudinal term (survival proportion
per each time point for a certain period ), which are shown in Table 4.1. What is
missing in Table 4.1 was only the variance per survival proportion which is useful
when we amalgamated the outcomes of these studies but all the variances were in-
cluded when the data was analysed. The study separated univariate meta-analyses
at each time point using both fixed and random effect models. All were performed
by R-software, using metafor package.
Univariate fixed effect model meta-analysis
Figure 5.1, shows the forest plot of univariate fixed-effect meta-analyses of survival
proportion for seizure relapse after epilepsy for months 6, 12, 24, 36, 60 and 120
post-operative. The forest plot shows the survival proportion together with the cor-
responding 95% confidence interval (CI) for each study. The weight for each study
is represented by the area of the box whose center also represents the size of effect
sizes (survival) estimated from that study. The 95% confidence interval for effect
sizes is represented by the horizontal bars. The length of horizontal bars is inversely
proportional to the precision of the estimate for that study (that is, the shorter hori-
zontal bar indicates more precisely the confidence interval, which is associated with
the smaller standard error and large sample sizes). The overall survival proportion
is shown by the middle of the diamond symbol whose left and right extremes repre-
sent the corresponding 95% confidence interval.
Table 5.1: Fixed effect summary
Time SPa(95% CIb) (χ2 − p− value) No of studies AIC
Month 6 0.78 (0.76, 0.80) <0.0001 18 187.6024
Month
12
0.76 (0.74, 0.78) <0.0001 18 137.6421
Month 24 0.70 (0.0.67, 0.72) <0.0001 18 99.98
Month 36 0.66 (0.64, 0.69) <0.0001 18 108.8651
Month 60 0.61 (0.59, 0.64) <0.0001 18 56.8070
Month 120 0.50 (0.47, 0.53) <0.0001 10 35.5992
aSP= survival proportion
bCI=confidence interval
Table 5.1 presents the results of the estimated summarized survival proportional
that was analysed using the fixed effect model meta-analysis. The estimated survival
at 6 months is 0.78, which means 78% of patients had not yet experienced a seizure
51
5.1. Fixed effect meta-analysis
month 6
FE Model
0.2 0.4 0.6 0.8 1 1.2
Observed Outcome
Study 18
Study 17
Study 16
Study 15
Study 14
Study 13
Study 12
Study 11
Study 10
Study 9
Study 8
Study 7
Study 6
Study 5
Study 4
Study 3
Study 2
Study 1
0.71 [0.59, 0.83]
0.73 [0.60, 0.86]
0.80 [0.75, 0.84]
0.98 [0.88, 1.07]
0.68 [0.63, 0.73]
0.67 [0.62, 0.73]
0.65 [0.50, 0.80]
0.57 [0.44, 0.71]
0.50 [0.38, 0.62]
0.32 [0.22, 0.43]
0.97 [0.92, 1.01]
0.90 [0.81, 0.98]
0.93 [0.79, 1.07]
0.80 [0.68, 0.92]
0.72 [0.57, 0.87]
0.56 [0.41, 0.72]
1.00 [0.91, 1.09]
0.74 [0.60, 0.88]
0.78 [0.76, 0.80]
month 12
FE Model
0 0.2 0.6 1 1.2
Observed Outcome
Study 18
Study 17
Study 16
Study 15
Study 14
Study 13
Study 12
Study 11
Study 10
Study 9
Study 8
Study 7
Study 6
Study 5
Study 4
Study 3
Study 2
Study 1
0.64 [0.49, 0.79]
0.68 [0.53, 0.84]
0.75 [0.70, 0.80]
0.98 [0.87, 1.08]
0.61 [0.55, 0.67]
0.61 [0.54, 0.67]
0.63 [0.47, 0.78]
0.56 [0.42, 0.70]
0.49 [0.32, 0.66]
0.23 [0.05, 0.42]
0.95 [0.91, 0.99]
0.85 [0.76, 0.94]
0.82 [0.68, 0.96]
0.76 [0.62, 0.90]
0.72 [0.54, 0.90]
0.56 [0.35, 0.76]
0.88 [0.79, 0.97]
0.58 [0.41, 0.75]
0.76 [0.74, 0.78]
Figure 5.1 – Fixed effect forest plot for month 6 and month 12
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month 24
FE Model
−0.2 0.2 0.6 1
Observed Outcome
Study 18
Study 17
Study 16
Study 15
Study 14
Study 13
Study 12
Study 11
Study 10
Study 9
Study 8
Study 7
Study 6
Study 5
Study 4
Study 3
Study 2
Study 1
0.58 [ 0.43, 0.74]
0.66 [ 0.50, 0.81]
0.68 [ 0.62, 0.73]
0.85 [ 0.74, 0.97]
0.54 [ 0.48, 0.60]
0.55 [ 0.48, 0.62]
0.61 [ 0.46, 0.77]
0.54 [ 0.40, 0.68]
0.44 [ 0.27, 0.62]
0.19 [−0.03, 0.40]
0.88 [ 0.83, 0.92]
0.77 [ 0.68, 0.86]
0.76 [ 0.61, 0.91]
0.65 [ 0.48, 0.82]
0.66 [ 0.48, 0.84]
0.47 [ 0.26, 0.68]
0.84 [ 0.74, 0.94]
0.55 [ 0.36, 0.74]
0.69 [ 0.67, 0.72]
month 36
FE Model
−0.2 0.2 0.6 1
Observed Outcome
Study 18
Study 17
Study 16
Study 15
Study 14
Study 13
Study 12
Study 11
Study 10
Study 9
Study 8
Study 7
Study 6
Study 5
Study 4
Study 3
Study 2
Study 1
0.56 [ 0.40, 0.73]
0.65 [ 0.49, 0.81]
0.65 [ 0.59, 0.70]
0.74 [ 0.62, 0.86]
0.47 [ 0.40, 0.54]
0.50 [ 0.43, 0.57]
0.61 [ 0.46, 0.77]
0.54 [ 0.40, 0.68]
0.44 [ 0.26, 0.63]
0.17 [−0.07, 0.41]
0.86 [ 0.82, 0.91]
0.75 [ 0.65, 0.84]
0.70 [ 0.53, 0.87]
0.53 [ 0.35, 0.71]
0.60 [ 0.40, 0.80]
0.45 [ 0.23, 0.67]
0.82 [ 0.72, 0.92]
0.52 [ 0.33, 0.71]
0.66 [ 0.64, 0.69]
Figure 5.1 – Continued Fixed effect forest plot for month 24 and month 36
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month 60
FE Model
−0.2 0.2 0.6 1
Observed Outcome
Study 18
Study 17
Study 16
Study 15
Study 14
Study 13
Study 12
Study 11
Study 10
Study 9
Study 8
Study 7
Study 6
Study 5
Study 4
Study 3
Study 2
Study 1
0.52 [ 0.36, 0.68]
0.55 [ 0.39, 0.71]
0.64 [ 0.58, 0.70]
0.59 [ 0.43, 0.76]
0.42 [ 0.35, 0.49]
0.48 [ 0.40, 0.55]
0.61 [ 0.39, 0.82]
0.54 [ 0.39, 0.68]
0.42 [ 0.24, 0.61]
0.15 [−0.11, 0.40]
0.74 [ 0.69, 0.79]
0.74 [ 0.64, 0.84]
0.68 [ 0.49, 0.87]
0.47 [ 0.18, 0.76]
0.60 [ 0.40, 0.80]
0.30 [ 0.07, 0.53]
0.78 [ 0.68, 0.88]
0.48 [ 0.28, 0.68]
0.61 [ 0.59, 0.64]
month 120
FE Model
−0.2 0.2 0.6
Observed Outcome
Study 10
Study 9
Study 8
Study 7
Study 6
Study 5
Study 4
Study 3
Study 2
Study 1
0.41 [ 0.24, 0.58]
0.60 [ 0.54, 0.66]
0.43 [ 0.14, 0.71]
0.33 [ 0.26, 0.40]
0.41 [ 0.33, 0.49]
0.13 [−0.15, 0.40]
0.47 [ 0.42, 0.53]
0.66 [ 0.56, 0.76]
0.30 [ 0.01, 0.59]
0.69 [ 0.58, 0.80]
0.50 [ 0.47, 0.53]
Figure 5.1 – Continued Fixed effect forest plot for month 60 and month 120
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5.2. Random effect meta-analysis
(seizure freedom) 6 months postoperative. The confidence interval tells us that we
are 95% confident that the survival (seizure freedom) at month 6 ranges from 76%
to 80%. At month 12, the pooled survival proportion tells us that 76% of patients
were on seizure freedom and the confidence interval varies from 74% to 78%. The
estimated pooled survival proportion is 0.7 after month 24 which implies that 70%
of patients had not yet experienced seizure after epilepsy surgery, and we are 95%
confident that the summarized survival proportion is between 0.67 and 0.72. After
36 months the estimated pooled survival proportion is 0.66 with a 0.64 to 0.69 con-
fidence interval. After 60 months (5 years postoperative) the estimated summarized
survival proportion is 0.61 with 95% confidence of 0.59 to 0.64 which means 61%
of patients have not yet experienced seizure after surgery. The estimated survival
after 10 years is 0.5 with 95% confidence interval of 0.47 to 0.53 (range of 0.6) which
means after 10 years only half of the patients had not experienced seizure relapse
after surgery.
The estimated pooled survival proportion was 0.78 at 6 months and decreased to
0.5 at 10 years (although there were 18 studies that were pooled for 6 months and
only 10 studies for 10 years). That is, 28% patients experienced seizure after surgery
between 6 months and 10 years. As was expected from the survival curve, it kept on
decreasing over time (as seizure relapsing) and it can be noted that the decrease was
large between 5 and 10 years, that is 9%.
The results suggest that heterogeneity was present in many time points that can
be visually observed from Figures 5.1 by poor overlapping of confidence interval. It
can also be noted that the study by McIntosh et al. (2012) had the worst proportion
of seizure freedom.
5.2 Random effect meta-analysis
In this model, we computed the summary survival proportion to determine if there
was any heterogeneity and the rate of variation between studies. In this model, the
assumption of fixed population effect sizes was relaxed. As in the previous section,
this model is still pooling the survival proportion at each time point separately.
We used the DerSimonian & Laird (1986) method for univariate random effect
meta-analysis for each time point (post-operative months) utilizing the R software
using DL method in metafor package. Figure 5.2 shows the forest plot of univari-
ate random effect meta-analyses of survival proportion for seizure freedom post-
operative for month 6, 12, 24, 36, 60 and 120 post-operative. Table 5.2 gives the
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month 6
RE Model
0.2 0.4 0.6 0.8 1 1.2
Observed Outcome
Study 18
Study 17
Study 16
Study 15
Study 14
Study 13
Study 12
Study 11
Study 10
Study 9
Study 8
Study 7
Study 6
Study 5
Study 4
Study 3
Study 2
Study 1
0.71 [0.59, 0.83]
0.73 [0.60, 0.86]
0.80 [0.75, 0.84]
0.98 [0.88, 1.07]
0.68 [0.63, 0.73]
0.67 [0.62, 0.73]
0.65 [0.50, 0.80]
0.57 [0.44, 0.71]
0.50 [0.38, 0.62]
0.32 [0.22, 0.43]
0.97 [0.92, 1.01]
0.90 [0.81, 0.98]
0.93 [0.79, 1.07]
0.80 [0.68, 0.92]
0.72 [0.57, 0.87]
0.56 [0.41, 0.72]
1.00 [0.91, 1.09]
0.74 [0.60, 0.88]
0.74 [0.66, 0.82]
month 12
RE Model
0 0.2 0.6 1 1.2
Observed Outcome
Study 18
Study 17
Study 16
Study 15
Study 14
Study 13
Study 12
Study 11
Study 10
Study 9
Study 8
Study 7
Study 6
Study 5
Study 4
Study 3
Study 2
Study 1
0.64 [0.49, 0.79]
0.68 [0.53, 0.84]
0.75 [0.70, 0.80]
0.98 [0.87, 1.08]
0.61 [0.55, 0.67]
0.61 [0.54, 0.67]
0.63 [0.47, 0.78]
0.56 [0.42, 0.70]
0.49 [0.32, 0.66]
0.23 [0.05, 0.42]
0.95 [0.91, 0.99]
0.85 [0.76, 0.94]
0.82 [0.68, 0.96]
0.76 [0.62, 0.90]
0.72 [0.54, 0.90]
0.56 [0.35, 0.76]
0.88 [0.79, 0.97]
0.58 [0.41, 0.75]
0.69 [0.61, 0.77]
Figure 5.2 – Random effect forest plot for month 6 and month 12
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month 24
RE Model
−0.2 0.2 0.6 1
Observed Outcome
Study 18
Study 17
Study 16
Study 15
Study 14
Study 13
Study 12
Study 11
Study 10
Study 9
Study 8
Study 7
Study 6
Study 5
Study 4
Study 3
Study 2
Study 1
0.58 [ 0.43, 0.74]
0.66 [ 0.50, 0.81]
0.68 [ 0.62, 0.73]
0.85 [ 0.74, 0.97]
0.54 [ 0.48, 0.60]
0.55 [ 0.48, 0.62]
0.61 [ 0.46, 0.77]
0.54 [ 0.40, 0.68]
0.44 [ 0.27, 0.62]
0.19 [−0.03, 0.40]
0.88 [ 0.83, 0.92]
0.77 [ 0.68, 0.86]
0.76 [ 0.61, 0.91]
0.65 [ 0.48, 0.82]
0.66 [ 0.48, 0.84]
0.47 [ 0.26, 0.68]
0.84 [ 0.74, 0.94]
0.55 [ 0.36, 0.74]
0.64 [ 0.56, 0.71]
month 36
RE Model
−0.2 0.2 0.6 1
Observed Outcome
Study 18
Study 17
Study 16
Study 15
Study 14
Study 13
Study 12
Study 11
Study 10
Study 9
Study 8
Study 7
Study 6
Study 5
Study 4
Study 3
Study 2
Study 1
0.56 [ 0.40, 0.73]
0.65 [ 0.49, 0.81]
0.65 [ 0.59, 0.70]
0.74 [ 0.62, 0.86]
0.47 [ 0.40, 0.54]
0.50 [ 0.43, 0.57]
0.61 [ 0.46, 0.77]
0.54 [ 0.40, 0.68]
0.44 [ 0.26, 0.63]
0.17 [−0.07, 0.41]
0.86 [ 0.82, 0.91]
0.75 [ 0.65, 0.84]
0.70 [ 0.53, 0.87]
0.53 [ 0.35, 0.71]
0.60 [ 0.40, 0.80]
0.45 [ 0.23, 0.67]
0.82 [ 0.72, 0.92]
0.52 [ 0.33, 0.71]
0.60 [ 0.52, 0.68]
Figure 5.2 – Continued Random effect forest plot for month 24 and month 36
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month 60
RE Model
−0.2 0.2 0.6 1
Observed Outcome
Study 18
Study 17
Study 16
Study 15
Study 14
Study 13
Study 12
Study 11
Study 10
Study 9
Study 8
Study 7
Study 6
Study 5
Study 4
Study 3
Study 2
Study 1
0.52 [ 0.36, 0.68]
0.55 [ 0.39, 0.71]
0.64 [ 0.58, 0.70]
0.59 [ 0.43, 0.76]
0.42 [ 0.35, 0.49]
0.48 [ 0.40, 0.55]
0.61 [ 0.39, 0.82]
0.54 [ 0.39, 0.68]
0.42 [ 0.24, 0.61]
0.15 [−0.11, 0.40]
0.74 [ 0.69, 0.79]
0.74 [ 0.64, 0.84]
0.68 [ 0.49, 0.87]
0.47 [ 0.18, 0.76]
0.60 [ 0.40, 0.80]
0.30 [ 0.07, 0.53]
0.78 [ 0.68, 0.88]
0.48 [ 0.28, 0.68]
0.56 [ 0.48, 0.63]
month 120
RE Model
−0.2 0.2 0.6
Observed Outcome
Study 10
Study 9
Study 8
Study 7
Study 6
Study 5
Study 4
Study 3
Study 2
Study 1
0.41 [ 0.24, 0.58]
0.60 [ 0.54, 0.66]
0.43 [ 0.14, 0.71]
0.33 [ 0.26, 0.40]
0.41 [ 0.33, 0.49]
0.13 [−0.15, 0.40]
0.47 [ 0.42, 0.53]
0.66 [ 0.56, 0.76]
0.30 [ 0.01, 0.59]
0.69 [ 0.58, 0.80]
0.47 [ 0.38, 0.56]
Figure 5.2 – Continued Random effect forest plot for month 60 and month 120
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summary overall of random effect model meta-analysis, the outcomes of every time
point, that is survival proportion and associated confidence interval, the heterogene-
ity p-value, and the value of heterogeneity not by chance (I2).
The estimated pooled survival proportional at 6 months postoperative is 0.74 and
95% confidence interval of (0.66, 0.82), which means that according to random ef-
fect model there were 74 % of the patients who experienced seizure 6 months after
surgery and we are 95% confident that survival proportion will vary from 66% to
82%. There exists 93.45% heterogeneity between studies. At 12 months postop-
erative it was estimated that there were 69% of patients who remained free from
seizure after surgery, with a 0.61 to 0.77 95% confidence interval. The estimated sur-
vival proportion at 24 months is 0.64 which means 64% of patients achieved seizure
freedom in this time interval and with 95% confidence the survival is expected to
vary from 56% to 71%. At 36 months postoperative it was estimated that the sur-
vival proportion is 0.6 which means that 60% of patients were not yet experiencing
seizure relapse after surgery, with 95% confidence that the survival proportion vary
from 0.54 to 0.68. At 60 months (5 years) postoperative it was estimated that 56% of
patients achieved seizure freedom, with 95% confidence that the seizure freedom is
between 48% and 63%. At 120 months (10 years) the estimated survival proportion
is 0.47.
It can be noted that the percentage of relapse from 6 months to 120 months post-
operative was estimated to be 27%. It can also be noted that the survival rate kept
on decreasing as the time passed (as expected from the survival time data of only
one event expected to happen), and one can notice that between 60 months and 120
months, the estimated survival proportion decreased by 9% which is large between
those time intervals that are displayed in the table. That may be because of the large
interval of 5 years.
The τ2 represent the estimation of variation between studies (between studies
variance) using the DL method (we can also observe that in Table 5.2). One can
notice that the largest estimate of τ2 is at month 6, which means there were more
variation between studies at this time point; as we observe from Figure 5.2 there is a
poor overlapping of confidence interval. It can also be noted that the estimated value
of τ2 is smaller (that is 0.0153) in month 120. The reason for that might be caused
by the few studies that are included in that month (less included studies that are 10
studies while the other time points had 18 studies) and it can be visually observed in
the forest of month 120 plot (that is Figure 5.2) that there is some (not much because
the heterogeneity is still present) overlapping of confidence interval.
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5.3. Summary
Table 5.2: Random effect summary
Time SPa(95% CIb) χ2 (p− value) studies τ2 I2c(%) AIC
Month 6 0.74 (0.66, 0.82) <0.0001 18 0.0258 93.45 -7.4952
Month 12 0.69 (0.61, 0.77) <0.0001 18 0.0255 91.64 -8.0692
Month 24 0.64 (0.56, 0.71) <0.0001 18 0.022 89.68 -10.994
Month 36 0.60 (0.52, 0.68) <0.0001 18 0.0253 90.11 -11.6189
Month 60 0.56 (0.48, 0.63) <0.0001 18 0.01818 85.42 -12.9689
Month 120 0.47 (0.38, 0.56) <0.0001 10 0.0153 87.31 -4.3749
aSP= survival proportion
bCI=confidence interval
cI2=Statistics test of heterogeneity not by chance
The significance of heterogeneity between studies is present. This is shown in
Table 5.2, column 3, all p-values are less than 0.05 and the I2 (the estimation of het-
erogeneity of between studies not only by chance, that is estimation of true hetero-
geneity) test values are larger than 80% in all 6 time points.
5.3 Summary
This chapter analyzed the data using the univariate meta-analysis. What can be
noted about this model is that it gives the summary of the survival proportion for
each time-point. We can also note that the results are different from fixed and ran-
dom effect model, the fixed effect has greater summary survival proportion values
than a random effect. When we look at the measure of goodness of fit the fixed ef-
fect has the larger values of Akaike Information Criteria (AIC) compared to random
effect model (the smaller the value the best the goodness of fit). That suggested that
the random effect model was the best model to fit this data compare to the fixed
effects effect model.
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Chapter 6
Meta-survival analysis
In this chapter, survival analysis is used to meta analyse the data, that is random and
fixed effect models.
6.1 Meta-Survival analysis in single-arm
There are 18 studies that are considered in this study, where study i has j (j=1,2,...,J)
time points, where the survival probability was observed. What can be noted in this
section is that we are not pooling the survival proportion at each time point sepa-
rately (which we did in the previous chapter ). This chapter uses the methodology
that was discussed in section 3.6.
We computed the conditional probability for study i ( i = 1, 2, ..., 18) for time
point j (j=1,2,...,6), using the published survival probability of postoperative seizure
freedom. Equation 3.50 was used to compute the conditional probability. Then the
arcsine was used to transform conditional survival probability and it was corrected
by 0.5. All this is well articulated in equation 3.51 and 3.52 and was used to compute
the variance of conditional survival probability.
The transformed conditional probability for study i was taken as a vector for all
j time-points, and its covariance matrix (that is diagonal since the conditional prob-
ability are not correlated and the diagonal variance was the variance for study i
that was computed using equation 3.52). Then the conditional probabilities for all
18 studies were pooled using equation 3.40 also the covariance matrix of the pooled
conditional probability was estimated using equation 3.41. This estimation was done
for both fixed and random effects models. What can be noted is that the covariance
matrix estimates has ∆ = 0 for fixed effect model and for the random effect model
the extended DerSimonian and Laird method was used to estimate ∆ (covariance
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6.2. Results
Table 6.1: Summary of random and fixed effect model: The transformed pooled conditional
probability π̂ and survival probability
Fixed effect Random Effect
Follow-upa π̂iFE
b
(SEc) S(t) [95% CId] π̂iRE
e
(SE) S(t) [95% CI]
6 1.1173(0.0097) 0.8081 (0.7932, 0.8232) 1.0636 (0.0544) 0.7655 (0.6808, 0.8613)
12 1.3308(0.00110) 0.7624 (0.7463, 0.7788) 1.3157(0.0270) 0.7140 (0.6246, 0.8163)
24 1.2640(0.0114) 0.6928 (0.6753, 0.7108) 1.2641(0.0121) 0.6462 (0.5614, 0.7438)
36 1.3529(0.0119) 0.6605 (0.6425, 0.6789) 1.3409 (0.0286) 0.6105 (0.5225, 0.7133)
60 1.3061(0.0125) 0.6153 (0.5967, 0.6344) 1.3013 (0.0347) 0.5700 (0.4892, 0.6641)
120 1.1322(0.0141 0.5043 (0.4845, 0.5250) 1.1613 (0.0574) 0.4755 (0.4078, 0.5545)
aFollow up in months
bFixed effect
cStandard error
dConfidence interval
eRandom effect
matrix estimates). Equation 3.53 was used to back pooled transformation condi-
tional probability to get the conditional probability and then we used it on estimat-
ing the summary of survival probability the product-limit method (that is equation
3.54) used and the delta method was used to estimate the variance of the summary
of survival probability. All this analysis was done using the R version 3.45. The
package MetaSurv was used to analyze the data and to plot the estimated survival
curve.
6.2 Results
The follow-up ranged from 6 months - 180 months and there was only one study
that ended after 180 months. Our issue was that we can only pool two or more
studies, hence our analysis ended at 120 months. It can be noted that the arcsine
transformed conditional probability for study i at j time point (although this is not
given in Table 6.1) was the lowest for the lowest number of patients at risk, while the
variance of the transformed conditional probability was higher. The pooled arcsine
transformed conditional survival probability and standard error is given for both
random and fixed model in Table 6.1.
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Figure 6.1 – Survival curves of the overall seizure freedom for the postoperative patients in
the 18 studies of meta-analysis. The grey lines represent the survival in each
study and the black square is the end of follow-up. The thick red line the
summarized survival curve of seizure freedom with a 95% confidence inter-
val(dashed red line) Obtained using the MetaSurv with fixed effect
Table 6.1 gives the results of the pooled conditional probability and the standard
error for every time point (that is πi and the S.E(πi.) for both the fixed effect model
and the random effect model, and it also gives the results of summarized survival
probability for both fixed and random effect models.
63
6.2. Results
0 50 100 150
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Time
S
ur
vi
va
l
Figure 6.2 – Survival curves of the overall seizure freedom for the postoperative patients in
the 18 studies of meta-analysis. The grey lines represent the survival in each
study and the black square is the end of follow-up. The thick red line repre-
sent the summarized survival curve of seizure freedom with a 95% confidence
interval (dashed red line) obtained using the MetaSurv with random effect
The estimated πi for the fixed effect model are large for time point 36 months
which indicates that there were large conditional probabilities in this time point.
There is a small standard error in month 12 which indicates there was large num-
ber of patients at risk at this time point, while as expected, at 120 months of follow
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up, the standard error is larger than the other 5 time points, since they were fewer
patients at risk at that time point. One can notice the increase of the standard er-
ror which indicates a decreasing number of patients at risk of seizure relapse with
time period increased (which indicates that most patients have already had seizure
relapse).
Also in Table 6.1, the estimated πi for the random effect model is large at 36 months
of follow-up and the standard error at 120 months time points which might be the
result of large random effect in these time points. The estimated πi are similar for 4
time points except for 6 months of follow up and 120 months of follow- up; this can
be well explained by the weight allocated on that time- points (using the variance).
Also in Table 6.1, the summary of survival probability estimation is given, to-
gether with their 95% confidence interval that was obtained using the extension of
Greenwoods formula, for both fixed and random effect model.
The summarized survival probability estimation in fixed effect model at 6 months
of follow up is 0.8081, which means that 80.81% patients had not yet experienced
seizure relapse 6 months post-operative, and we are 95% confident that the sum-
mary survival will vary from 79.32% to 82.32%. At 12 months of follow-up the esti-
mated summary of survival probability was 0.7624, which means 76.24% of patients
achieved seizure freedom after 12 months postoperative and we are 95% confidence
that the summarized survival probability will vary from 74.63% to 77.88%. The sum-
mary survival probability was estimated to be 0.6928 at 24 months postoperative
with 95% confidence interval of 0.6753 to 0.7108. At 36 months of follow- up the
estimated survival probability is found to be 0.6605, which means that 66.05 % of pa-
tients have not yet experienced seizure relapse 36 months postoperative, with 95%
confidence that the summarize survival probability will vary from 64.25% to 67.89%.
The estimated summary survival probability was found to be 0.6153 at 60 months
post-operative and with 95% confidence that the summary survival probability will
vary from 0.5967 to 0.6344. At 120 months (10 years) of follow up the estimated sum-
marized survival probability is 0.5043, which means 50.43% of patients were seizure
free at 10 years postoperative, with a 95% confidence that the summarized survival
probability varies from 48.45% to 52.50%.
Figure 6.1 gives the estimated fixed effects survival curves (which are plotted in
grey) from the 18 published studies. By observing the graph, one can notice incon-
sistent seizure freedom (from different published studies) because they are spread
all over the graphs over time. The estimated summarized survival probability is
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plotted in red, while the 95% confidence interval is plotted in dashed red, which is
narrow and that might suggest that the standard error of this model is small. From
the red plotted curve, one can notice that at 6 months of postoperative, the seizure
freedom was 80%. This means that about 20% of patients who underwent opera-
tions have already experienced seizure relapse in a short time of 6 months. One can
also notice that the median of seizure freedom is slightly greater than 120 months
(10 years) of postoperative.
Table 6.1 also gives the estimation of the random effect model. At 6 months of
follow up the summary survival probability estimation is 0.7665 with a 95% confi-
dence interval of 0.6808 and 0.8613, which means that 76.65% of patients had not
yet experienced seizure relapse 6 months postoperative with 95% confidence that
the summary varied form 68.08% to 86.13%. The estimated summary survival prob-
ability estimation at 12 months of follow up is 0.7140, which means that 71.4% of
patients were still seizure free at 12 months postoperative. At 24 months of postop-
erative the estimated summary of seizure probability is 0.6462 and the confidence in-
terval 0.5614 and 0.7438, which can be interpreted to indicate that 64.62% of patients
were seizure free at 24 months postoperative with 95% confidence that summary of
seizure probability will vary from 56.14 % to 74.38%. The estimated summary of sur-
vival probability is 0.6105 at 36 months of follow up with a 95% confidence interval
of 0.5225 to 0.7133. At 60 months (5 years) of follow up, the estimated summarized
survival probability is 0.57, with a 95% confidence interval of 0.4892 to 0.6641, which
means 57% of patients were still free from seizure relapse 60 months postoperative
with a 95% confidence that the summarized survival probability is from 48.92% to
66.41%. At 120 months (10 years) of follow up the estimated summarized survival
probability is 0.4755, which means that 47.55% of patients were still on seizure free-
dom at 120 months postoperative.
Figure 6.2 gives the estimated random effects survival curves (that estimates the
seizure freedom over time) that are plotted in grey for all 18 included studies. The
estimated summarized survival probability is plotted in red, while the 95% confi-
dence interval is plotted in dashed red. The 95% confidence interval is wider than
that of the fixed effect model, which might be an indication of a large standard error
(which might be true since the survival curves of the published studies are all over
the graph. This might be an indication of variation between the studies that means
the heterogeneity is present. From the red plotted curve, one can notice that at 6
months of postoperative the seizure freedom was approximately 77%, which means
about 23% (if we ignore the censored patients) of patients who underwent the oper-
ation have have already experienced a seizure relapse in a short time of 6 months.
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One can also notice that the median seizure freedom time is less than 120 months (10
years) of postoperative.
Heterogeneity was present, since the value of heterogeneity statistics is Q = 880.7
and was significant and the I2 = 90.58%. This confirms that the random effect
approach is reasonable for this data. The result of the median survival time was
found to be 104.46 months (almost 9 years) using the random effect model. These
were found in the analysis using R statistical software. Although it is not given in
the Table, we will show how to estimate it in Appendix 7.3.
The summary survival estimates of the fixed effect model are systematically larger
than the summary survival estimates of the random effect model. The presence of
random effect increase the variance of the published survival estimates, which that
may be the reason of the confidence interval of random effects to be wider than that
of the fixed effects.
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Epilepsy affects 1% of the younger age population and 3% of the older age popu-
lation, regardless of gender or race (Browne & Holmes, 2008). It can be estimated
that there might be some increase of proportion if there were also more studies in
developing world that focused on it (Hirtz et al., 2007; Seneneyake & Román, 1993;
Newton & Garcia, 2012; Birbeck et al., 2002). Although it increases the risk of death
by 1.6 to 4.1 (standardized mortality ratio) of the general population, it is a control-
lable disease (Hitiris et al., 2007), (Shorvon et al., 2015b). The concern with epilepsy
patients are those patients with parmacoresistante epilepsy, which is been found
to be costly, especially when medical treatment is being used to diagnosed condi-
tion of patients, while there is no seizure freedom is being achieved (Forsgren et al.,
2005),(that threatens the quality of life in an individual).
One suggested option for drug resistant patients is surgical treatment. Successful
surgery treatment has increase from 1986 to 1999 from 43% to 85% (Panel, 1990; En-
gel Jr et al., 2003; Engel Jr, 1993). In a paper by Engel Jr et al. (2003), the proportion
of achieving seizure freedom after the epilepsy surgery was 63.2% with a 95% con-
fidence interval of (60%; 66%). This was a result of short term outcome (less than
5 years) of seizure after epilepsy surgery. In 2005 Téllez-Zenteno et al. (2005) was
concerned with the long term outcome of seizure after epilepsy surgery, then they
did the review of the studies that were done for 5 years or more and their pooled
outcome proportion was 66% with a 95% confidence interval (62, 70) of patients
who achieve seizure freedom in temporal lobe. These studies show some good clin-
ical results on achievement of seizure freedom on patients, but the concern was that
some of the studies in Téllez-Zenteno et al. (2005) just give the proportion at the end
of follow-up without giving the proportion within the follow-up (lack of using the
survival analysis methods which have some advantage on that).
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In this study, we had 18 studies which include study that had 3 trials with different
patients and different times. The 18 studies were observed at 6 time points ( 6, 12,
24, 36 ,60 and 120 post-operative months). The survival on seizure was observed at
these time points.
Univariate analysis was performed by pooling the proportion of seizure freedom
in separate time points (months 6, months 12, months 24, months 36, months 60 and
months 120). Since the AIC of random effect was less than that of fixed effect model
(that is for fixed effect model greater than 35, while for random effect less than −4)
the random effect model was the best model of analyzing our data, and the summary
proportion of seizure freedom keep on decreasing with time. Although the surgical
treatments can be regarded as the best treatment in refractory epilepsy, some patients
experience seizure relapse (Téllez-Zenteno et al., 2005). Most of the included studies
have high seizure freedom soon after the surgery (within 5 years)(except (McIntosh
et al., 2012; Elsharkawy et al., 2008).
The non-parametric method to analyze the survival probability in studies that
have only single arm treatment that was proposed by Combescure et al. (2014) was
used to pool the quantitative data. This is the right method to summarize the sur-
vival estimator from the aggregate data (result from published articles) to model the
fixed and random effect model. To compare this method with the separated time
point analysis, it has some of these advantages: the pooled survival probability at
time t involves all the results of the studies ending before this particular time-point,
which that may enlarge the 95% confidence interval. It also gives the variation be-
tween studies in the same time-point and also between time-points.
It was the right decision to use it since time to seizure relapse is not a rare event
which was going to the underestimate the proportion of seizure freedom if that was
the case. In many studies, the number of patients at risk was reported. If that was
not the case, it was calculated, since this methods required to give accurate variation
to weight the conditional survival probability.
There was no method used to compare the fixed and random effect model in mul-
tivariate analysis. However, since the true heterogeneity between studies percent-
age is high, it was decided to only discuss the results from the random effect model.
Based on the results, there was a bigger proportion of seizure relapse 6 months post-
operative. Since the seizure freedom proportion is 0.7655 which means that about
23% of patients had already experienced seizures 6 months after surgery. This is
quite a big proportion of patients who failed in such a short period. This might
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be the result of incomplete epilepsy surgery because of many seizure relapses that
occur immediately after surgery. The reason of early seizure relapse post-operative
surgery might be: new seizure foci developed (Wieser & Hane, 2003), the frontal lobe
has a large size which that might be the cause of incomplete surgery (Téllez-Zenteno
et al., 2005). Overall from all the studies, survival after surgery is substantially low.
7.1 Limitations
Deciding on the inclusion criteria was a challenge. Some studies were based on
the common studies that were dealing with the long-term seizure outcomes (Téllez-
Zenteno et al., 2005; Toninia et al., 2004), some were based on the strategy of how to
deal with the longitudinal data (Ishak et al., 2007; Musekiwa et al., 2016), and some
on how to analyze meta-analysis survival time data (Arends, 2006; Taghavi, 2014;
Combescure et al., 2014). Our study time points were also based on the included
studies, that had the large interval between two time points especially month 36 and
month 60 (interval period of 2 years); and the interval between month 60 and month
120. This can result in underrate proportion between these time points.
This thesis was more concerned with only surgical treatment (only resective surgery
studies), but to also perform meta-analysis of studies that compare the survival per
time of patients between two arm (surgery and medicine) might be of interest. There
is also one known random clinical trials studies that compared the surgery and
medicine, to increase those studies may increase the clinical solution to the drug
resistance patients. To use two arms studies will be a better option of using the pa-
rameter estimation method that suggested by Arends (2006) in random effect model
meta-analysis and the co-variance structure that was used in Musekiwa et al. (2016)
studies to know the correlation proportion between two time points.
7.2 Area of future research
This study only focused on one effect size, survival (S(t)). It is also important to
analyze other effect sizes in one study. Therefore the model can be extended to
be able to incorporate multiple effect sizes. Secondly, since missing data is one of
the common problems in longitudinal studies, it is also important to address and
incorporate advanced missing data techniques in the case where some studies have
missing observations at particular time points.
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7.3 Conclusion
This study performed a systematic review to come up with studies that performed
survival analysis on epilepsy after a surgery. Eighteen studies fitted in the inclu-
sion criteria from these we found that about 50% of the patients who undergo the
treatment will relapse within 10 years. It is, therefore, advised that clinicians may
continue looking for more and efficient treatment methods that have a life- long suc-
cessful treatment. Meta-analysis has proved to be a good approach in amalgamating
all the findings from all over the world.
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Appendix A
A.1 Summary survival rate variance
We taken the idea of individual data, where we get the variance of the survival rate
of non-parametric estimation, using the Greenwood formula, by delta method ap-
plication. Using the Combescure et al. (2014) proposal to get the variance of pooled
survival rate. Let us assume we have (t1, t2, ....tJ ) then we logarithm equation 3.54,
then we apply the delta method to get the variance of logarithm of pooled survival
rate. For simplicity let us start by getting the scalar variance of the pooled survival
rate, we know that the delta method is given as:
var(f(x)) ≈ (f ′(E(x)))2var(x) (7.1)
which in our case it derived to be:
var(log( ˆS(tj))) = 4
j∑
s=1
var(π̂s)
tan2(π̂s)
(7.2)
If we derive equation for covariance matrix case, derive it using the the pooled π̂ we
get:
var(log( ˆS(tj))) = 4
∑
u≤j
∑
v≤j
[
cov(π̂u; π̂v)
tan(π̂u) tan(π̂v)
[
(7.3)
what can be noted with equation 7.3 is that when there is an assumption of fixed
effect model the cov(π̂u; π̂v) = 0 for u 6= v (Combescure et al., 2014). We must also
note that this variance will hold if the pooled survival rate is normally distribution
( that is if the pooled conditional probability is not close to one (Combescure et al.,
2014)). The variance was used to get the 95% confidence interval
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Appendix B
B.1 Estimation of the pooled median time
From Combescure et al. (2014) proposal it show how to estimate pooled median sur-
vival time, let us denote the median survival time by τm, using the linear interpo-
lation of the summary survival curve between two survival time point tmandtm−1,
where the pooled ˆS(tm < 0.5 and ˆS(tm−1 > 0.5, then we can calculate the pooled
median survival time as:
τm = tm − (tm − tm−1)
ˆS(tm)− 0.5
ˆS(tm)− ˆS(tm−1)
(7.4)
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R codes
C.1 R code
C.1.1 Univariate analysis
univariate analysis Data¡-read.csv(”C:
Users
Smilo
Google Drive
SOME PART OF INTRO
smylo254.csv”) fixed effect model univariate that separate the effect sizes between
time points
m6= rma(yi, vi, data=Data[DataTime == 6, ],method = ”FE”)m12 = rma(yi, vi, data =
Data[DataTime==12,], method = ”FE”) m24= rma(yi, vi, data=Data[DataTime ==
24, ],method = ”FE”)m36 = rma(yi, vi, data = Data[DataTime==36,], method =
”FE”) m60= rma(yi, vi, data=Data[DataTime == 60, ],method = ”FE”)m120 =
rma(yi, vi, data = Data[DataTime==120,], method = ”FE”) summary(m6); sum-
mary(m12);summary(m24);summary(m36);summary(m60); summary(m120)
random effect model univariate that separate the effects sizes between time points
n6= rma(yi, vi, data=Data[DataTime == 6, ],method = ”DL”)n12 = rma(yi, vi, data =
Data[DataTime==12,], method = ”DL”) n24= rma(yi, vi, data=Data[DataTime ==
24, ],method = ”DL”)n36 = rma(yi, vi, data = Data[DataTime==36,], method =
”DL”) n60= rma(yi, vi, data=Data[DataTime == 60, ],method = ”DL”)n120 =
rma(yi, vi, data = Data[DataTime==120,], method = ”DL”) the summary for sur-
vival proportion in fixed effect summary(n6); summary(n12);summary(n24);summary(n36);summary(n60);
summary(n120)
forest plot of the fixed effect of eachh and every time point forest(m6, main=”month
6”) forest(m12, main=”month 12”) par(mfrow=c(1,2)) forest(m24, main=”month 24”)
forest(m36, main=”month 36”) par(mfrow=c(1,2)) forest(m60, main=”month 60”)
forest(m120, main=”month 120”)
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forest plot of the random effect of eachh and every time point par(mfrow=c(1,2))
forest(n6, main=”month 6”) forest(n12, main=”month 12”) par(mfrow=c(1,2)) for-
est(n24, main=”month 24”) forest(n36, main=”month 36”) par(mfrow=c(1,2)) for-
est(n60, main=”month 60”) forest(n120, main=”month 120”)
C.1.2 Multivariate analysis
multivariate analysis Data5¡-read.csv(”C:
Users
Smilo
Google Drive
SOME PART OF INTRO
smylo2351.csv”) Times ¡- Data5TimeSurvival < −Data5Survival Study ¡- Data5studyP lottingthepublishedsurvivalrateofseizurefreedomicurveforistudyplot(Times, Survival, type =
”n”, ylim = c(0, 1), xlab = ”Time”, ylab = ”Survival”)for(iinunique(sort(Study)))lines(Times[Study == i], Survival[Study == i], type = ”l”, col = ”red”)points(max(Times[Study == i]), Survival[Study == iT imes == max(Times[Study == i])], pch = 15)BeforethisweinstallmvtnormpackagetoallowmultivariateanalysisandmetaSurvpackagethatallowDLextendmultivariatetoestimatethebetweenstudyvar−
covariancedata(Data5)attach(Data5)results < −msurv(study, T ime,NbRisk, Survival, confidence =
”Greenwood”)resultsSummarysurvivalplotandconfidenceinterval1stforRandomeffect
to estimate summary survival analysis RandomEffectSummary¡- resultssummary.randomRandomEffectSummaryFixedEffectSummary <
−resultssummary.fixed FixedEffectSummary
Plotting the estimated summary survival curve with 95plot(Time, Survival, type=”n”,
col=”grey”, ylim=c(0,1),xlab=”Time”, ylab=”Survival”) for (i in unique(sort(Study)))
lines(Time[Study==i], Survival[Study==i], type=”l”, col=”grey”) points(max(Time[Study==i]),
Survival[Study==i Time==max(Time[Study==i])], pch=15) lines(RandomEffectSummary[,1],
RandomEffectSummary[,2], type=”l”, col=”red”, lwd=3) points(RandomEffectSummary[,1],
RandomEffectSummary[,3], type=”l”, col=”red”, lty=3, lwd=3) points(RandomEffectSummary[,1],
RandomEffectSummary[,4], type=”l”, col=”red”, lty=3, lwd=3)
Summary survival plot and confidence interval 1st for fixed effect FixedEffectSummary¡-
resultssummary.fixedF ixedEffectSummaryplot(Time, Survival, type = ”n”, col =
”grey”, ylim = c(0, 1), xlab = ”Time”, ylab = ”Survival”)for(iinunique(sort(Study)))lines(Time[Study == i], Survival[Study == i], type = ”l”, col = ”grey”)points(max(Time[Study == i]), Survival[Study == iT ime == max(Time[Study == i])], pch = 15)lines(FixedEffectSummary[, 1], F ixedEffectSummary[, 2], type =
”l”, col = ”red”, lwd = 3)points(FixedEffectSummary[, 1], F ixedEffectSummary[, 3], type =
”l”, col = ”red”, lty = 3, lwd = 3)points(FixedEffectSummary[, 1], F ixedEffectSummary[, 4], type =
”l”, col = ”red”, lty = 3, lwd = 3)
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